Coronavirus vaccine

EP4469080A2Inactive Publication Date: 2024-12-04BIONTECH SE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2023708311
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-01-18
Filing Date
2023-01-27
Publication Date
2024-12-04
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current COVID-19 vaccines face challenges in providing broad and long-lasting immunity against emerging SARS-CoV-2 variants, such as Omicron, due to antigenic drift and immune escape, necessitating improved immunogenic strategies.

Method used

Administration of RNA encoding SARS-CoV-2 spike protein antigens from multiple variants, including Wuhan, Alpha, Beta, Delta, and Omicron strains, to induce synergistic immune responses with enhanced neutralization titers and broader cross-protection, potentially using bivalent vaccines and multiple doses to optimize antibody affinity.

Benefits of technology

This approach elicits improved immune responses with broader cross-neutralization capabilities and reduced susceptibility to immune escape, providing better protection against current and future variants, including Omicron sublineages, and maintaining efficacy over time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1.1
    Figure 1.1
Patent Text Reader

Abstract

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and / or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CORONAVIRUS VACCINE

[0002] This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and / or T cell responses. These methods and agents are, in particular, useful for the prevention or treatment of coronavirus infection. Administration of RNA disclosed herein to a subject can protect the subject against coronavirus infection. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen. Administering to the subject RNA encoding vaccine antigen may provide (following expression of the RNA by appropriate target cells) vaccine antigen for inducing an immune response against vaccine antigen (and disease-associated antigen) in the subject.

[0003] Coronaviruses are positive-sense, single-stranded RNA ((+)ssRNA) enveloped viruses that encode for a total of four structural proteins, spike protein (S), envelope protein (E), membrane protein (M) and nucleocapsid protein (N). The spike protein (S protein) is responsible for receptor-recognition, attachment to the cell, infection via the endosomal pathway, and the genomic release driven by fusion of viral and endosomal membranes. Though sequences between the different family members vary, there are conserved regions and motifs within the S protein making it possible to divide the S protein into two subdomains: SI and S2. While the S2, with its transmembrane domain, is responsible for membrane fusion, the S1 domain recognizes the virus-specific receptor and binds to the target host cell. Within several coronavirus isolates, the receptor binding domain (RBD) was identified and a general structure of the S protein defined (Figure 1).

[0004] In December 2019, a pneumonia outbreak of unknown cause occurred in Wuhan, China and it became clear that a novel coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) was the underlying cause. The genetic sequence of SARS-CoV-2 became available to the WHO and public (MN908947.3) and the virus was categorized into the betacoronavirus subfamily. By sequence analysis, the phylogenetic tree revealed a closer relationship to severe acute respiratory syndrome (SARS) virus isolates than to another coronavirus infecting humans, namely the Middle East respiratory syndrome (MERS) virus.

[0005] SARS-CoV-2 infections and the resulting disease COVID-19 have spread globally, affecting a growing number of countries. On 11 March 2020 the WHO characterized the COVID-19 outbreak as a pandemic. As of 01 December 2020, there have been >63 million globally confirmed COVID-19 cases and >1.4 million deaths, with 191 countries / regions affected. The ongoing pandemic remains a significant challenge to public health and economic stability worldwide.

[0006] Every individual is at risk of infection as there is no pre-existing immunity to SARS-CoV-2. Following infection some but not all individuals develop protective immunity in terms of neutralising antibody responses and cell mediated immunity. However, it is currently unknown to what extent and for how long this protection lasts. According to WHO 80% of infected individuals recover without need for hospital care, while 15% develop more severe disease and 5% need intensive care. Increasing age and underlying medical conditions are considered risk factors for developing severe disease.

[0007] The presentation of COVID-19 is generally with cough and fever, with chest radiography showing ground-glass opacities or patchy shadowing. However, many patients present without fever or radiographic changes, and infections may be asymptomatic which is relevant to controlling transmission. For symptomatic subjects, progression of disease may lead to acute respiratory distress syndrome requiring ventilation and subsequent multi-organ failure and death. Common symptoms in hospitalized patients (in order of highest to lowest frequency) include fever, dry cough, shortness of breath, fatigue, myalgias, nausea / vomiting or diarrhoea, headache, weakness, and rhinorrhoea. Anosmia (loss of smell) or ageusia (loss of taste) may be the sole presenting symptom in approximately 3% of individuals who have COVID-19.

[0008] All ages may present with the disease, but notably case fatality rates (CFR) are elevated in persons >60 years of age. Comorbidities are also associated with increased CFR, including cardiovascular disease, diabetes, hypertension, and chronic respiratory disease. Healthcare workers are overrepresented among COVID-19 patients due to occupational exposure to infected patients.

[0009] In most situations, a molecular test is used to detect SARS-CoV-2 and confirm infection. The reverse transcription polymerase chain reaction (RT-PCR) test methods targeting SARS-CoV-2 viral RNA are the gold standard in vitro methods for diagnosing suspected cases of COVID-19. Samples to be tested are collected from the nose and / or throat with a swab.

[0010] Among other things, the present disclosure provides insights into immune responses elicited by exposure to (e.g., by vaccination and / or infection) different SARS-CoV-2 variants or immunogenic polypeptides (e.g., S protein), or immunogenic fragments thereof. For example, in some embodiments, administering RNA encoding an S protein of a BA.2 and / or BA.4 / 5 Omicron SARS-CoV-2 variant, or an immunogenic fragment thereof, can result in an improved immune response, which includes, e.g., improved neutralization of Omicron BA.4 and / or Omicron BA.5 SARS-CoV-2 variants and / or broader cross-neutralization of variants (e.g., Omicron variants) of concern (e.g., increased neutralization titers against a larger number of variants (e.g., Omicron variants) of concern). In some embodiments, the present disclosure provides an insight that a bivalent coronavirus vaccine (e.g., a bivalent BA.4 / 5 vaccine comprising a first RNA encoding a SARS-CoV-2 S protein of a Wuhan strain or an immunogenic fragment thereof, and a second RNA encoding a SARS-CoV-2 S protein comprising one or more mutations that are characteristic of a BA.4 / 5 Omicron variant or an immunogenic fragment thereof) can provide broader cross-neutralization against SARS-CoV-2 Wuhan strain and certain variants thereof (e.g., in some embodiments variants that are prevalent and / or rapidly spreading in a relevant jurisdiction, e.g., certain Omicron variants) in certain subjects as compared to a monovalent coronavirus vaccine (e.g., a vaccine comprising RNA encoding a SARS-CoV-2 S protein of a coronavirus strain or variant thereof). In some embodiments, such broader cross-neutralization can be observed in vaccine-naive subjects. In some embodiments, such broader cross-neutralization can be observed in subjects without a coronavirus infection (e.g., a SARS-CoV-2 infection). In some embodiments, such broader cross-neutralization can be observed in subjects who previously received a SARS-CoV-2 vaccine (e.g., in some embodiments an RNA vaccine encoding a SARS-CoV-2 S protein, e.g., in some embodiments of a Wuhan strain). In some embodiments, such broader cross- neutralization can be observed in in young pediatric subjects (e.g., subjects aged 6 months to less than 2 years, and / or 2 years to less than 5 years).

[0011] In some embodiments, the present disclosure provides an insight that exposure to at least two certain SARS-CoV-2 variants or immunogenic polypeptides (e.g., S protein), or immunogenic fragments thereof can result in an synergistic improvement in immune response (e.g., higher neutralization titers, broader cross-neutralization, and / or an immune response that is less susceptible to immune escape) as compared to exposure to one SARS-CoV-2 strain and / or other combinations of SARS-CoV-2 variants. In some embodiments, the present disclosure provides an insight that exposure to a S protein from a Wuhan strain or an immunogenic fragment thereof (e.g., by vaccination and / or infection), and exposure to a S protein of an Omicron BA.1 variant or an immunogenic fragment thereof (e.g., by vaccination and / or infection) can result in an synergistic improvement in immune response (e.g., higher neutralization titers, broader cross-neutralization, and / or an immune response that is less susceptible to immune escape) as compared to exposure to one SARS-CoV-2 strain and / or other combinations of SARS-CoV-2 variants). In some embodiments, the present disclosure provides an insight that exposure to a S protein from a Wuhan strain or an immunogenic fragment thereof (e.g., by vaccination and / or infection), and exposure to a S protein of an Omicron BA.4 or BA.5 variant or an immunogenic fragment thereof (e.g., by vaccination and / or infection) can result in an synergistic improvement in immune response (e.g., higher neutralization titers, broader cross-neutralization, and / or an immune response that is less susceptible to immune escape) as compared to exposure to one SARS-CoV-2 strain and / or other combinations of SARS-CoV-2 variants). In some embodiments, the present disclosure provides an insight that (i) exposure to a S protein from a strain / variant selected from the group consisting of Wuhan strain, an alpha variant, beta variant, delta variant, Omicron BA.1, and sublineages derived from any of the aforementioned strains / variants, or immunogenic fragments thereof (e.g., by vaccination and / or infection), combined with (ii)exposure to a S protein from a strain / variant selected from the group consisting of Omicron BA.2, Omicron BA.4, Omicron BA.5, and sublineages derived from any of the aforementioned strains / variants, or immunogenic fragments thereof (e.g., by vaccination and / or infection) can result in an synergistic improvement in immune response (e.g., higher neutralization titers, broader cross-neutralization, and / or an immune response that is less susceptible to immune escape) as compared to exposure to one SARS-CoV-2 strain and / or other combinations of SARS-CoV-2 variants).

[0012] The present disclosure also provides significant insights into how an immune response develops in subjects following exposures to (e.g., vaccinations and / or infections) multiple, different SARS-CoV-2 strains. Among other things, disclosed herein is a finding that different combinations of SARS-CoV-2 variants elicit different immune responses. Specifically, the present disclosure provides an insight that exposure to certain combinations of SARS-CoV-2 variants can elicit an improved immune response (e.g., higher neutralization titers, broader cross-neutralization, and / or an immune response that is less susceptible to immune escape). In some embodiments, an improved immune response can be produced when subjects are delivered two or more antigens (e.g., as polypeptides or RNAs encoding such polypeptides), each having few shared epitopes. In some embodiments, an improved immune response can be produced when subjects are delivered a combination of SARS-CoV-2 S proteins (e.g., as polypeptides or RNAs encoding such polypeptides) sharing no more than 50% (e.g., no more than 40%, no more than 30%, no more 20% or more) of epitopes (including, e.g., amino acid mutations) that can be bound by neutralization antibodies. In some embodiments, an improved immune response can be produced by delivering, as polypeptides or RNAs encoding such polypeptides, (a) a SARS-CoV-2 S protein from a Wuhan strain, an Alpha variant, Beta variant, or a Delta variant of SARS-CoV-2 or an immunogenic fragment thereof, and (b) an S protein from a SARS-CoV-2 Omicron variant or an immunogenic fragment thereof. In some embodiments, an improved immune response can be produced by delivering, as polypeptides or RNAs encoding such polypeptides, (a) a SARS-CoV-2 S protein from a Wuhan strain, an Alpha variant, a Beta variant, or a Delta variant of SARS-CoV-2 or an immunogenic fragment thereof, and (b) an S protein of a SARS-CoV-2 Omicron variant that is not a BA.1 Omicron variant or an immunogenic fragment thereof. In some embodiments, an improved immune response can be produced by delivering, as polypeptides or RNAs encoding such polypeptides, (a) an S protein from a Wuhan strain, an Alpha variant, a Beta Variant, a Delta SARS-CoV-2 variant, or a BA.1 Omicron variant or an immunogenic fragment thereof and (b) an S protein of a SARS-CoV-2 Omicron variant that is not a BA.1 Omicron variant or an immunogenic fragment thereof. In some embodiments, an improved immune response can be produced by delivering, as polypeptides or RNAs encoding such polypeptides, (a) a SARS-CoV-2 S protein from a Wuhan strain, an Alpha variant, a Beta variant, or a Delta variant, or an immunogenic fragment thereof and (b) an S protein of a BA.2 or a BA.4 or BA.5 SARS-CoV-2 Omicron variant or an immunogenic fragment thereof.

[0013] In some embodiments, the present disclosure also provides an insight that administration of multiple doses (e.g., at least 2, at least 3, at least 4, or more doses) of a coronavirus vaccine described herein (e.g., a bivalent vaccine described herein such as a bivalent BA.4 / 5 vaccine) may provide certain beneficial effect(s) on affinity of antibodies against one or more SARS- CoV-2 strain or variants thereof. In some embodiments, such beneficial effect(s) on affinity of antibodies may be observed with respect to antibodies against certain Omicron variants. By way of example only, in some embodiments, such beneficial effect(s) on affinity of antibodies may be observed with respect to antibodies against certain Omicron variants that share at least one or more common epitopes, for example, with a Wuhan strain.

[0014] Also disclosed herein are compositions that can produce an improved immune response (e.g., an immune response having broader cross-neutralization activity, stronger neutralization, and / or which is less susceptible to immune escape). In some embodiments, a composition described herein comprises two or more antigens or nucleic acids (e.g., RNA) that encodes such antigens that have few shared epitopes. In some embodiments, a composition described herein delivers, as polypeptides or nucleic acids encoding such polypeptides, a combination of SARS-CoV-2 S proteins or immunogenic fragments thereof sharing no more than 50% (e.g., no more than 40%, no more than 30%, no more than 20% or more) of epitopes (including, e.g., amino acid mutations) that can be bound by neutralization antibodies. In some embodiments, a composition described herein comprises (a) RNA encoding a SARS-CoV-2 S protein from a Wuhan strain, an Alpha variant, a Beta variant, or a Delta variant or an immunogenic fragment thereof and (b) RNA encoding an S protein from an Omicron variant of SARS-CoV-2 (e.g., in some embodiments an S protein from a BA.1, BA.2, or BA.4 / 5 Omicron variant) or an immunogenic fragment thereof. In some embodiments, a composition described herein comprises (a) RNA encoding a SARS-CoV-2 S protein from a Wuhan strain, an Alpha variant, a Beta variant, or a Delta variant or an immunogenic fragment thereof and (b) RNA encoding an S protein of an Omicron variant of SARS-CoV-2 that is not a BA.1 Omicron variant or an immunogenic fragment thereof. In some embodiments, a composition described herein comprises (a) RNA encoding a SARS-CoV-2 S protein of a Wuhan strain, an Alpha variant, a Beta variant, or a Delta variant or a BA.1 Omicron variant or an immunogenic fragment thereof and (b) RNA encoding an S protein of a Omicron variant that is not a BA.1 Omicron variant or an immunogenic fragment thereof. In some embodiments, a composition described herein comprises (a) RNA encoding a SARS-CoV-2 S protein of a Wuhan strain, an Alpha variant, a Beta variant or a Delta variant of SARS-CoV-2 and (b) RNA encoding an S protein from a BA.2 or a BA.4 or BA.5 Omicron variant of SARS-CoV-2 or an immunogenic fragment thereof. In some embodiments, a composition described herein comprises RNA encoding an S protein from a BA.2 Omicron variant of SARS-CoV-2 or an immunogenic fragment thereof. In some embodiments, a composition comprises RNA encoding an S protein from a BA.4 or BA.5 Omicron variant of SARS-CoV-2 or an immunogenic fragment thereof.

[0015] SARS-CoV-2 is an RNA virus with four structural proteins. One of them, the spike protein is a surface protein which binds the angiotensin-converting enzyme 2 (ACE-2) present on host cells. Therefore, the spike protein is considered a relevant antigen for vaccine development.

[0016] BNT162b2 (SEQ ID NO: 20) is an mRNA vaccine for prevention of COVID-19 and demonstrated an efficacy of 95% or more at preventing COVID-19. The vaccine is made of a 5'capped mRNA encoding for the full-length SARS-CoV-2 spike glycoprotein (S) encapsulated in lipid nanoparticles (LNPs). The finished product is presented as a concentrate for dispersion for injection containing BNT162b2 as active substance. Other ingredients are: ALC-0315 (4- hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), ALC-0159 (2-

[0017] [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide), 1,2-Distearoyl-sn-glycero-3- phosphocholine (DSPC), cholesterol, potassium chloride, potassium dihydrogen phosphate, sodium chloride, disodium phosphate dihydrate, sucrose and water for injection.

[0018] In some embodiments, a different buffer may be used in lieu of PBS. In some embodiments, the buffer is formulated in a Tris-buffered solution. In some embodiments, the formulation comprises ALC-0315 (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), ALC-0159 (2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide), DSPC (1,2-distearoyl- sn-glycero-3-phosphocholine), cholesterol, sucrose, trometamol (Tris), trometamol hydrochloride and water.

[0019] In some embodiments, the concentration of the RNA in the pharmaceutical RNA preparation is about 0.1 mg / ml. In some embodiments about 30 ug of RNA is administered by administering about 200 uL of RNA preparation. In some embodiments, the RNA in the pharmaceutical RNA preparation is diluted prior to administration (e.g., diluted to a concentration of about 0.05 mg / ml). In some embodiments, the administration volumes are between about 200 μl and about 300 μl. In some embodiments, the RNA in pharmaceutical RNA preparation is formulated in about 10 mM Tris buffer, and about 10% sucrose.

[0020] In some embodiments, the concentration of RNA in a pharmaceutical RNA preparation is about 0.1 mg / ml, and is formulated in about 10 mM Tris buffer, about 10% sucrose and a dose of about 10 μg of RNA is administered by diluting the pharmaceutical RNA preparation about 1:1 and administering about 200 μl of diluted pharmaceutical RNA preparation. In some embodiments, the concentration of RNA in a pharmaceutical RNA preparation is about 0.1 mg / ml, and is formulated in about 10 mM Tris buffer, about 10% sucrose and a dose of the RNA of about 10 μg is administered by diluting the pharmaceutical RNA preparation about 1:5.75 and administering about 200 μ olf diluted pharmaceutical RNA preparation.

[0021] The sequence of the SARS-CoV-2 S protein of a Wuhan strain disclosed herein was chosen based on the sequence for the "SARS-CoV-2 isolate Wuhan-Hu -1": GenBank: MN908947.3 (complete genome) and GenBank: QHD43416.1 (spike surface glycoprotein).

[0022] In some embodiments, an active substance consists of a single-stranded, 5'-capped codon- optimized mRNA that is translated into the spike antigen of SARS-CoV-2. In some embodiments, an encoded spike antigen protein sequence contains two proline mutations, which stabilize an antigenically optimal pre-fusion confirmation (P2 S). In some embodiments, an RNA does not contain any uridines; e.g., instead of uridine the modified Nl- methylpseudouridine can be used in RNA synthesis. mRNA disclosed herein can be translated into the SARS-CoV-2 S protein in a host cell. The S protein can then be expressed on the cell surface where it can induce an adaptive immune response. The S protein can be identified as a target for neutralising antibodies against the virus and is considered a relevant vaccine component.

[0023] BNT162b2 can be administered intramuscularly (IM) in two 30 μg doses of the diluted vaccine solution given about 21 days apart (e.g., to adult vaccine naive subjects (i.e., subjects 12 years and older who have not previously been administered a SARS-CoV-2 vaccine)).

[0024] The recent emergence of novel circulating variants of SARS-CoV-2 has raised significant concerns about geographic and temporal efficacy of vaccine interventions. One of the earliest variants that emerged and rapidly became globally dominant was D614G.

[0025] The alpha variant (also known as B.1.1.7, VOC202012 / 01, 501Y.V1 or GRY) was initially detected in the United Kingdom. The alpha variant has a large number of mutations, including several mutations in the S gene. It has been shown to be inherently more transmissible, with a growth rate that has been estimated to be 40-70% higher than other SARS-CoV-2 lineages in multiple countries (Volz et al., 2021, Nature, https: / / doi.org / 10.1038 / s41586-021-03470-x; Washington et al., 2021, Cell https: / / doi.Org / 10.1016 / j.cell.2021.03.052).

[0026] The beta variant (also known as B.1.351 or GH / 501Y.V2) was first detected in South Africa. The beta variant carries several mutations in the S gene. Three of these mutations are at sites in the RBD that are associated with immune evasion: N501Y (shared with alpha) and E484K and

[0027] K417N. The gamma variant (also known as P.1 or GR / 501Y.V3) was first detected in Brazil. The gamma variant carries several mutations that affect the spike protein, including two shared with beta (N501Y and E484K), as well as a different mutation at position 417 (K417T).

[0028] The delta variant (also known as B.1.617.2 or G / 478K.V1) was first documented in India. The delta variant has several point mutations that affect the spike protein, including P681R (a mutation position shared with alpha and adjacent to the furin cleavage site), and L452R, which is in the RBD and has been linked with increased binding to ACE2 and neutralizing antibody resistance. There is also a deletion in the spike protein at position 156 / 157.

[0029] These four VOCs have circulated globally and became dominant variants in the geographic regions where they were first identified.

[0030] On 24 November 2021, the Omicron (B.1.1.529) variant was first reported to WHO from South Africa.

[0031] SARS-CoV-2 Omicron and its sublineages have had a major impact on the 20 epidemiological landscape of the COVID-19 pandemic since initial emergence in November 2021 (WHO Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE): Classification of Omicron (B.l.1.259): SARS-CoV-2 Variant of Concern (2021); WHO Headquarters (HQ), WHO Health Emergencies Programme, Enhancing Response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States (2022)). Significant alterations in the spike (S) glycoprotein of the first Omicron variant BA.1 leading to the loss of many neutralizing antibody epitopes (M. Hoffmann et al., "The Omicron variant is highly resistant against antibody mediated neutralization: Implications for control of the COVID-19 pandemic", Cell 185, 447- 456.ell (2022)) rendered BA.1 capable of partially escaping previously established SARS-CoV- 2 wild-type strain (Wuhan-Hu-l)-based immunity (V. Servellita, et al., "Neutralizing 30 immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants", Cell 185, 1539-1548. e5 (2022); Y. Cao et al., "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies", Nature 602, 657-663 (2022)). Hence, breakthrough infection of vaccinated individuals with Omicron are more common than with previous Variants of Concern (VOCs). While Omicron BA.1 was displaced by the BA.2 variant in many countries around the globe, other variants such as BA.1.1 and BA.3 temporarily and / or locally gained momentum but did not become globally dominant (S. Xia et al., "Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. Signal Transduct. Target. Ther. 7, 241 (2022); H. Gruell et al., "SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns, Cell Host Microbe 7 , 241 (2022).). Omicron BA.2.12.1 subsequently displaced BA.2 to become dominant in the United States, whereas BA.4 and BA.5 displaced BA.2 in Europe, parts of Africa, and Asia / Pacific (H. Gruell et al., "SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns," Cell Host Microbe 7, 241 (2022); European Centre for Disease Prevention and Control, Weekly COVID- 19 country overview -Country overview report: Week 31 2022 (2022); J. Hadfield et al., "Nextstrain: Real-time tracking of pathogen evolution," Bioinformatics 34, 4121-4123 (2018)). Currently, Omicron XBB.1.5 is dominant globally, including in the United States (Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: US Department of Health and Human Services, CDC; 2023, January 22. https: / / covid.cdc.gov / coviddata-tracker (2022)). Omicron has acquired numerous alterations (amino acid exchanges, insertions, or deletions) in the S glycoprotein, among which some are shared between all Omicron VOCs while others are specific to one or more Omicron sublineages. Antigenically, BA.2.12.1 exhibits high similarity with BA.2 but not BA.1, whereas BA.4 and BA.5 differ considerably from their ancestor BA.2 and even more so from BA.1, in line with their genealogy (A. Z. Mykytyn et al., "Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct," Sci. Immunol. 7, eabq4450 (2022).). Major differences of BA.1 from the remaining Omicron VOCs include A143-145, L212I, or ins214EPE in the S glycoprotein N-terminal domain and G446S or G496S in the receptor binding domain (RBD). Amino acid changes T376A, D405N, and R408S in the RBD are in turn common to BA.2 and its descendants but not found in BA.1. In addition, some alterations are specific for individual BA.2-descendant VOCs, including L452Q for BA.2.12.1 or L452R and F486V for BA.4 and BA.5 (BA.4 and BA.5 encode for the 30 same S sequence). Most of these shared and VOC-specific alterations were shown to ay μ aln important role in immune escape from monoclonal antibodies and polyclonal sera raised against the wild-type S glycoprotein. In particular, the BA.4 / BA.5-specific alterations are strongly implicated in immune escape of these VOCs (P. Wang et al., "Antibody resistance of SARS-CoV-2 variants B.1.351 and B.l.1.7. Nature 593, 130-135 (2021); Q. Wang et al., "Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5. Nature 608, 5

[0032] 603-608 (2022)). Summary

[0033] The present disclosure generally embraces the immunotherapeutic treatment of a subject comprising the administration of RNA, i.e., vaccine RNA, encoding an amino acid sequence, i.e., a vaccine antigen, comprising SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or the immunogenic variant thereof, i.e., an antigenic peptide or protein. Thus, the vaccine antigen comprises an epitope of SARS- CoV-2 S protein for inducing an immune response against coronavirus S protein, in particular SARS-CoV-2 S protein, in the subject. RNA encoding vaccine antigen is administered to provide (following expression of the polynucleotide by appropriate target cells) antigen for induction, i.e., stimulation, priming and / or expansion, of an immune response, e.g., antibodies and / or immune effector cells, which is targeted to target antigen (coronavirus S protein, in particular SARS-CoV-2 S protein) or a procession product thereof. In one embodiment, the immune response which is to be induced according to the present disclosure is a B cell-mediated immune response, i.e., an antibody-mediated immune response. Additionally or alternatively, in one embodiment, the immune response which is to be induced according to the present disclosure is a T cell-mediated immune response. In one embodiment, the immune response is an anti-coronavirus, in particular anti-SARS-CoV-2 immune response.

[0034] Vaccines described herein comprise as an active principle single-stranded RNA that may be translated into protein upon entering cells of a recipient. In addition to wildtype or codon- optimized sequences encoding the antigen sequence, the RNA may contain one or more structural elements optimized for maximal efficacy of the RNA with respect to stability and translational efficiency (e.g., 5' cap, 5' UTR, 3' UTR, poly(A)-tail, or combinations thereof). In one embodiment, the RNA contains all of these elements. In one embodiment, a capl structure may be utilized as specific capping structure at the 5'-end of the RNA drug substance. In one embodiment, beta-S-ARCA(D1) (m27'2'-OGppSpG) or m27'3'-OGppp(m12'-O)ApG may be utilized as specific capping structure at the 5’-end of the RNA drug substances. As 5’-UTR sequence, the 5’-UTR sequence of the human alpha-globin mRNA, optionally with an optimized 'Kozak sequence' to increase translational efficiency (e.g., SEQ ID NO: 12) may be used. As 3’-UTR sequence, a combination of two sequence elements (Fl element) derived from the "amino terminal enhancer of split" (AES) mRNA (called F) and the mitochondrial encoded 12S ribosomal RNA (called I) (e.g., SEQ ID NO: 13) placed between the coding sequence and the poly(A)-tail to assure higher maximum protein levels and prolonged persistence of the mRNA may be used. These were identified by an ex vivo selection process for sequences that confer RNA stability and augment total protein expression (see WO 2017 / 060314, herein incorporated by reference). Alternatively, the 3'-UTR may be two re-iterated 3’-UTRs of the human beta-globin mRNA.

[0035] Additionally or alternatively, in some embodiments, an RNA comprises a poly(A)-tail comprising a length of at least 90 adenosine nucleotides (including, e.g., at least about 100 adenosine nucleotides, at least about 110 adenosine nucleotides, at least about 120 adenosine nucleotides, at least about 130 adenosine nucleotides, or longer). In some embodiments, a poly(A)-tail may comprise a length of about 90 to about 150 adenosine nucleotides (e.g., about 100 to about 150 adenosine nucleotides). In some embodiments a poly(A)-tail may comprise an interrupted poly(A)-tail. For example, in some such embodiments, a poly(A)-tail measuring about 90 to about 120 nucleotides in length (e.g., about 110 nucleotides in length), consisting of a stretch of about 30 adenosine residues (e.g., about 28, about 29, about 30, about 31, or about 32 adenosine residues), followed by a linker sequence of about 10 nucleotides (of random nucleotides, e.g., about 9, about 10, or about 11 random nucleotides) and another about 70 adenosine nucleotides (e.g., about 65, about 66, about 67, about 68, about 69, about 70, about 71, about 72, about 73, about 74, or about 75 adenosine nucleotides) may be used (e.g., a poly(A) tail comprising SEQ ID NO: 14). This poly (A)-tail sequence was designed to enhance RNA stability and translational efficiency.

[0036] Furthermore, in some embodiments, a nucleotide sequence encoding a secretory signal peptide (sec) may be fused to the antigen-encoding regions preferably in a way that the sec is translated as an N terminal tag. In one embodiment, sec corresponds to the secretory signal peptide of a SARS-CoV-2 S protein. In some embodiments, sequences coding for short linker peptides predominantly consisting of the amino acids glycine (G) and serine (S), as commonly used for fusion proteins may be used as GS / Linkers to join a secretory signal and an antigenic polypeptide.

[0037] Vaccine RNA described herein may be complexed with proteins and / or lipids, preferably lipids, to generate RNA-particles for administration. If a combination of different RNAs is used, the RNAs may be complexed together or complexed separately with proteins and / or lipids to generate RNA-particles for administration.

[0038] In one aspect, the disclosure features a composition or medical preparation comprising an RNA encoding a SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein the SARS-CoV-2 S polypeptide or fragment comprises: (a) an amino acid sequence having at least 85% 90% 91% 92% 93% 94% 95% 96% 97% 98% 99% or 100% identity to SEQ ID NO:1, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:1: (1) D985P, V987P, F817P, A892P, A899P, and A942P; (2) K986P, V987P, F817P, A892P, A899P, and A942P; (3) D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (4) K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (5) D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (6) D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; (7) K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; or (8) D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; (b) an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (c) an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (d) an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0039] In some embodiments, the RNA comprises a modified nucleoside in place of uridine. In some embodiments, the RNA comprises modified uridines in place of all uridines. In some embodiments, the RNA comprises N1-methyl-pseudouridine (m1ψ) in place of all uridines. In some embodiments, the RNA comprises a 5' cap. In some embodiments, the 5' cap is or comprises m27'3'-OGppp(m12'-O)ApG.

[0040] In some embodiments, the RNA comprises a 5'-UTR that is or comprises a modified human alpha-globin 5'-UTR. In some embodiments, the RNA comprises a 5' UTR comprising the nucleotide sequence of SEQ ID NO: 12, or a nucleotide sequence that is at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO: 12.

[0041] In some embodiments, the RNA comprises a 3'-UTR that is or comprises a first sequence from the amino terminal enhancer of split (AES) messenger RNA and a second sequence from the mitochondrial encoded 12S ribosomal RNA. In some embodiments, the RNA comprises a 3' UTR comprising the nucleotide sequence of SEQ ID NO: 13, or a nucleotide sequence that is at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO: 13.

[0042] In some embodiments, the RNA comprises a poly-A sequence. In some embodiments, the poly-A sequence comprises at least 100 nucleotides. In some embodiments, the poly-A sequence comprises 30 adenine nucleotides followed by 70 adenine nucleotides, wherein the 30 adenine nucleotides and 70 adenine nucleotides are separated by a linker sequence. In some embodiments, the poly-A sequence comprises or consists of the nucleotide sequence of SEQ ID NO: 14, or a nucleotide sequence that is at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO: 14.

[0043] In some embodiments, the RNA is formulated or is to be formulated for intramuscular administration. In some embodiments, the RNA is formulated or is to be formulated as particles. In some embodiments, the particles are lipid nanoparticles (LNPs) or lipoplex (LPX) particles. In some embodiments, the LNPs comprise ((4-hydroxybutyl)azanediyl)bis(hexane-

[0044] 6.1-diyl)bis(2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide,

[0045] 1.2-Distearoyl-sn-glycero-3-phosphocholine, and cholesterol. In some embodiments, the lipoplex particles are obtainable by mixing the RNA with liposomes.

[0046] In some embodiments, the RNA is mRNA or saRNA.

[0047] In some embodiments, the composition or medical preparation is a pharmaceutical composition. In some embodiments, the composition or medical preparation is a vaccine.

[0048] In some embodiments, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers, diluents and / or excipients. In another aspect, the present disclosure provides a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:1: (1) D985P, V987P, F817P, A892P, A899P, and A942P; (2) K986P, V987P, F817P, A892P, A899P, and A942P; (3) D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (4) K986P, V987P, F817P,

[0049] A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (5) D985P, K986P, V987P, F817P,

[0050] A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (6) D985P, V987P, F817P, A892P,

[0051] A899P, A942P, R682G, R683S, and R685S; (7) K986P, V987P, F817P, A892P, A899P, A942P,

[0052] R682G, R683S, and R685S; or (8) D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S.

[0053] In one aspect, the present disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0054] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85% 90% 91% 92% 93% 94% 95% 96% 97% 98% 99% or 100% identity to SEQ ID NO:1; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0055] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0056] Another aspect of the disclosure provides a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:1: (1) D985P, V987P, F817P, A892P, A899P, and A942P; (2) K986P, V987P, F817P, A892P, A899P, and A942P; (3) D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (4) K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (5) D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (6) D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; (7) K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; or (8) D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S.

[0057] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0058] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S. Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0059] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:1: (1) D985P, V987P, F817P, A892P, A899P, and A942P; (2) K986P, V987P, F817P, A892P, A899P, and A942P; (3) D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (4) K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (5) D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (6) D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; (7) K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; or (8) D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S.

[0060] Another aspect of the disclosure features composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85% 90% 91% 92% 93% 94% 95% 96% 97% 98% 99% or 100% identity to SEQ ID NO:70; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0061] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0062] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0063] In one aspect, the disclosure provides a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or SEQ ID NO:105; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:1: (1) D985P, V987P, F817P, A892P, A899P, and A942P; (2) K986P, V987P, F817P, A892P, A899P, and A942P; (3) D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (4) K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (5) D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; (6) D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; (7) K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; or (8) D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S.

[0064] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or SEQ ID NQ:105; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S. Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or SEQ ID NO:105; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0065] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or SEQ ID NQ:105; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0066] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, and A942P; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0067] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, and A942P; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0068] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0069] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0070] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S. Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0071] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0072] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85% 90% 91% 92% 93% 94% 95% 96% 97% 98% 99% or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0073] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, and A942P; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0074] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, and A942P; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0075] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0076] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0077] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0078] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0079] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85% 90% 91% 92% 93% 94% 95% 96% 97% 98% 99% or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P;

[0080] (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0081] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;

[0082] (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0083] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, and A942P; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0084] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, and A942P; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0085] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0086] Another aspect of the disclosure features composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0087] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S. Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0088] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0089] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85% 90% 91% 92% 93% 94% 95% 96% 97% 98% 99% or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0090] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: D982P, V984P, F814P, A889P, A896P, and A939P; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0091] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: K983P, V984P, F814P, A889P, A896P, and A939P; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0092] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0093] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0094] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70: (1) D982P, V984P, F814P, A889P, A896P, and A939P; (2) K983P, V984P, F814P, A889P, A896P, and A939P; (3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; (4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or (5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

[0095] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: D982P, V984P, F814P, A889P, A896P, and A939P; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0096] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85% 90% 91% 92% 93% 94% 95% 96% 97% 98% 99% or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: K983P, V984P, F814P, A889P, A896P, and A939P; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0097] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0098] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0099] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0100] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises the following substitutions relative to SEQ ID NQ:70: D982P, V984P, F814P, A889P, A896P, and A939P; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0101] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises the following substitutions relative to SEQ ID NO:70: K983P, V984P, F814P, A889P, A896P, and A939P; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0102] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises the following substitutions relative to SEQ ID NQ:70: D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S. Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises the following substitutions relative to SEQ ID NO:70: K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0103] Another aspect of the disclosure features a composition or medical preparation comprising a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein: (a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises the following substitutions relative to SEQ ID NQ:70: D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and (b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105: (1) D980P, V982P, F812P, A887P, A894P, and A937P; (2) K981P, V982P, F812P, A887P, A894P, and A937P; (3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; (4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or (5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

[0104] The present disclosure, among other things, provides an insight that incorporation of a D985P mutation rather than a K986P mutation can improve protein express and / or immunogencity (e.g., improve neutralization response). In some embodiments, incorporation of D985P rather than K986P can provide such improvements when combined with one or more other proline mutations (e.g., one or more proline mutations disclosed herein). In some embodiments, incorporation of D985P rather than K986P can provide such improvements when combined with V987P (e.g., one or more proline mutations disclosed herein). In some embodiments, incorporation of D985P rather than K986P can provide such improvements when combined with one or more (e.g., all) of F817P, A892P, A899P, A942P, and V987P.

[0105] In some embodiments, the present disclosure provides an insight that RNA encoding a SARS- CoV-2 S protein comprising one or more proline mutations (e.g., one or more of the proline mutations and / or combination of proline mutations disclosed herein) and a mutated furin cleavage site can provide an improved immune response (e.g., an improved immune repsonse as compared to a similar or same construct comprising an intact furin cleavage site).

[0106] In some embodiments, the first RNA and the second RNA each comprise a modified nucleoside in place of uridine. In some embodiments, the first RNA and the second RNA each comprise modified uridines in place of all uridines. In some embodiments, the first RNA and the second RNA each comprise N1-methyl-pseudouridine (m1ψ) in place of all uridines.

[0107] In some embodiments, the first RNA and the second RNA each comprise a 5' cap. In some embodiments, the 5' cap comprises m27, 3'-OGppp(m12'-O)ApG.

[0108] In some embodiments, the first RNA and the second RNA each comprise a 5'-UTR that is or comprises a modified human alpha-globin 5'-UTR. In some embodiments, the first RNA and the second RNA each comprise a 5' UTR comprising the nucleotide sequence of SEQ ID NO: 12, or a nucleotide sequence that is at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO: 12.

[0109] In some embodiments, the first RNA and the second RNA each comprise a 3'-UTR that is or comprises a first sequence from the amino terminal enhancer of split (AES) messenger RNA and a second sequence from the mitochondrial encoded 12S ribosomal RNA. In some embodiments, the first RNA and the second RNA each comprise a 3' UTR comprising the nucleotide sequence of SEQ ID NO: 13, or a nucleotide sequence that is at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO: 13.

[0110] In some embodiments, the first RNA and the second RNA each comprise a poly-A sequence. In some embodiments, the first RNA and the second RNA each comprise a poly-A sequence that comprises at least 100 nucleotides. In some embodiments, the first RNA and the second RNA each comprise a poly-A sequence that comprises 30 adenine nucleotides followed by 70 adenine nucleotides, wherein the 30 adenine nucleotides and 70 adenine nucleotides are separated by a linker sequence. In some embodiments, the first RNA and the second RNA each comprise a poly-A sequence that comprises or consists of the nucleotide sequence of SEQ ID NO: 14, or a nucleotide sequence that is at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO: 14.

[0111] In some embodiments, the first RNA and the second RNA are each formulated or to be formulated for intramuscular administration.

[0112] In some embodiments, the first RNA and the second RNA are each formulated or to be formulated as particles. In some embodiments, the first RNA and the second RNA are each to be formulated as lipid nanoparticles (LNPs) or lipoplex (LPX) particles. In some embodiments, the LNPs comprise ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2- hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-Distearoyl- sn-glycero-3-phosphocholine, and cholesterol.

[0113] In some embodiments, the first RNA and the second RNA are formulated in separate LNPs. In some embodiments, the first RNA and the second RNA are formulated in the same LNP. In some embodiments, the lipoplex particles are obtainable by mixing the RNA with liposomes.

[0114] In some embodiments, the first RNA and the second RNA are each mRNA. In some embodiments, the first RNA and the second RNA are each saRNA.

[0115] In some embodiments, the composition or medical preparation is a pharmaceutical composition. In some embodiments, the composition or medical preparation is a vaccine.

[0116] In some embodiments, the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers, diluents and / or excipients.

[0117] In another aspect, the disclosure provides a method of inducing an immune response in a subject, the method comprising administering to the subject a composition or medical preparation described herein thereby inducing an immune response in the subject.

[0118] In some embodiments, the SARS-CoV-2 S polypeptide comprises an amino acid sequence that does not comprise a D985P substitution relative to SEQ ID NO:1; does not comprise a D982P substitution relative to SEQ ID NO:69 or SEQ ID NQ:70, or does not comprise a D980P substitution relative to SEQ ID NQ:104 or SEQ ID NQ:105.

[0119] In some embodiments, the method further comprises administering a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein the second SARS-CoV-2 S polypeptide or immunogenic fragment is a SARS-CoV-2 S polypeptide of an Omicron variant that is not a BA.1 Omicron variant. In some embodiments, the method further comprises administering a second, different RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein the second SARC-CoV-2 S polypeptide or fragment is selected from an SARS-CoV-2 S polypeptide or fragment described herein.

[0120] Another aspect of the disclosure provides a method of inducing an immune response in a subject, the method comprising administering to the subject the composition or medical preparation described herein, thereby inducing an immune response in the subject. In some embodiments, the SARS-CoV-2 S polypeptide comprises an amino acid sequence that does not comprise a D985P substitution relative to SEQ ID NO:1; does not comprise a D982P substitution relative to SEQ ID NO:69 or SEQ ID NQ:70, or does not comprise a D980P substitution relative to SEQ ID NQ:104 or SEQ ID NQ:105.

[0121] In some embodiments, the method further comprises administering a second composition or medical preparation, wherein the second composition or medical preparation comprises an RNA encoding an SARS-CoV-2 S polypeptide or an immunogenic fragment of an Omicron variant that is not a BA.1 Omicron variant.

[0122] In some embodiments, the method further comprises administering a second composition or medical preparation, wherein the second composition or medical preparation comprises a third RNA encoding a third SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a fourth RNA encoding a fourth SARS-CoV-2 S polypeptide or an immunogenic fragment thereof.

[0123] In some embodiments, the third RNA encodes an SARS-CoV-2 S polypeptide or an immunogenic fragment thereof that is a first or a second SARS-CoV-2 S polypeptide or immunogenic fragment thereof recited in any one of claims 24-102, and wherein the third RNA encodes a SARS-CoV-2 S polypeptide or fragment that is different from the first SARS- CoV-2 S polypeptide or fragment encoded by the first RNA and / or that is different from the second SARS-CoV-2 S polypeptide or fragment encoded by the second RNA.

[0124] In some embodiments, the fourth RNA encodes an SARS-CoV-2 S polypeptide or an immunogenic fragment thereof that is a first or a second SARS-CoV-2 S polypeptide or immunogenic fragment thereof recited in any one of claims 24-102, and wherein the fourth RNA encodes a SARS-CoV-2 S polypeptide or fragment that is different from the first SARS- CoV-2 S polypeptide or fragment encoded by the first RNA and / or that is different from the second SARS-CoV-2 S polypeptide or fragment encoded by the second RNA. In some embodiments, the third RNA encodes an SARS-CoV-2 S polypeptide or an immunogenic fragment thereof that is a first or a second SARS-CoV-2 S polypeptide or immunogenic fragment thereof recited in any one of claims 24-102, and wherein the third RNA encodes a SARS-CoV-2 S polypeptide or fragment that is different from the first SARS- CoV-2 S polypeptide or fragment encoded by the first RNA and that is different from the second SARS-CoV-2 S polypeptide or fragment encoded by the second RNA.

[0125] In some embodiments, the fourth RNA encodes an SARS-CoV-2 S polypeptide or an immunogenic fragment thereof that is a first or a second SARS-CoV-2 S polypeptide or immunogenic fragment thereof recited in any one of claims 24-102, and wherein the fourth RNA encodes a SARS-CoV-2 S polypeptide or fragment that is different from the first SARS- CoV-2 S polypeptide or fragment encoded by the first RNA and that is different from the second SARS-CoV-2 S polypeptide or fragment encoded by the second RNA.

[0126] In some embodiments, the third RNA encodes an SARS-CoV-2 S polypeptide or an immunogenic fragment thereof that is a first or a second SARS-CoV-2 S polypeptide or immunogenic fragment thereof recited in any one of claims 24-102, wherein the third RNA encodes a SARS-CoV-2 S polypeptide or fragment that is different from the first SARS-CoV-2 S polypeptide or fragment encoded by the first RNA and that is different from the second SARS- CoV-2 S polypeptide or fragment encoded by the second RNA, wherein the fourth RNA encodes an SARS-CoV-2 S polypeptide or an immunogenic fragment thereof that is a first or a second SARS-CoV-2 S polypeptide or immunogenic fragment thereof recited in any one of claims 24-102, wherein the fourth RNA encodes a SARS-CoV-2 S polypeptide or fragment that is different from the first SARS-CoV-2 S polypeptide or fragment encoded by the first RNA and that is different from the second SARS-CoV-2 S polypeptide or fragment encoded by the second RNA.

[0127] In some embodiments, each of the first, second, third, and fourth RNAs encodes a different SARS-CoV-2 S polypeptide or immunogenic fragment thereof.

[0128] In another aspect, a monovalent vaccine as described herein can be administered with a bivalent vaccine as described herein. For example, in some embodiments, a method of inducing an immune response comprises administering to a subject (i) a composition or medical preparation described herein that comprises an RNA encoding a SARS-CoV-2 S polypeptide or an immunogenic fragment thereof described herein and (ii) a composition or medical preparation comprising at least a first RNA encoding a first SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof as described herein. [DDM1] In some embodiments, the monovalent vaccine and the bivalent vaccine can be administered at least 3 weeks apart, including, e.g., at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, or longer. In some embodiments, the monovalent vaccine and the bivalent vaccine can be administered at least 3 months apart, including, e.g., at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, or longer. In some embodiments, the monovalent vaccine and the bivalent vaccine can be administered on different arms in a single session. In some embodiments, the monovalent vaccine and the bivalent vaccine can be administered as a trivalent vaccine in a single injection (e.g., mixing the monovalent and bivalent vaccines together prior to administration).

[0129] Brief description of the drawings

[0130] Figure 1. Schematic overview of the S protein organization of the SARS-CoV-2 S protein.

[0131] The sequence within the S1 subunit consists of the signal sequence (SS) and the receptor binding domain (RBD) which is the key subunit within the S protein which is relevant for binding to the human cellular receptor ACE2. The S2 subunit contains the S2 protease cleavage site (S2') followed by a fusion peptide (FP) for membrane fusion, heptad repeats (HR1 and HR2) with a central helix (CH) domain, the transmembrane domain (TM) and a cytoplasmic tail (CT).

[0132] Figure 2. Exemplary SARS-CoV-2 vaccine constructs.

[0133] Based on the full and wildtype S protein, we have designed different constructs encoding the (1) full protein with mutations in close distance to the first heptad repeat (HRP1) that include stabilizing mutations preserving neutralisation sensitive sites, the (2) d So1main or the (3) RB domain (RBD) only. Furthermore, to stabilize the protein fragments a fibritin domain (F) was fused to the C-terminus. All constructs start with the signal peptide (SP) to ensure Golgi transport to the cell membrane.

[0134] Figure 3. General structure of Certain RNA vaccines.

[0135] Schematic illustration of the general structure of certain RNA vaccines with 5’-cap, 5’- and 3’- untranslated regions, coding sequences with intrinsic secretory signal peptide as well as GS- linker, and poly(A)-tail. Please note that the individual elements are not drawn exactly true to scale compared to their respective sequence lengths.

[0136] UTR = Untranslated region; sec = Secretory signal peptide; RBD = Receptor Binding Domain; GS = Glycine-serine linker.

[0137] Figure 4. General structure of Certain RNA vaccines.

[0138] Schematic illustration of the general structure of certain RNA drug substances with 5’-cap, 5’- and 3’-untranslated regions, coding sequences with intrinsic secretory signal peptide as well as GS-linker, and poly(A)-tail. Please note that the individual elements are not drawn exactly true to scale compared to their respective sequence lengths. GS = Glycine-serine linker; UTR = Untranslated region; Sec = Secretory signal peptide; RBD = Receptor Binding Domain.

[0139] Figure 5. General structure of Certain RNA vaccines.

[0140] Schematic illustration of the general structure of RNA vaccines with 5'-cap, 5'- and 3'- untranslated regions, coding sequences of the Venezuelan equine encephalitis virus (VEEV) RNA-dependent RNA polymerase replicase and the SARS-CoV-2 antigen with intrinsic secretory signal peptide as well as GS-linker, and poly(A)-tail. Please note that the individual elements are not drawn exactly true to scale compared to their respective sequence lengths. UTR = Untranslated region; Sec = Secretory signal peptide; RBD = Receptor Binding Domain; GS = Glycine-serine linker.

[0141] Figure 6. Schematic overview of the S protein organization of the SARS-CoV-2 S protein and constructs for the development of a SARS-CoV-2 vaccine.

[0142] Based on the wildtype S protein, we have designed two different transmembrane-anchored RBD-based vaccine constructs encoding the RBD fragment fused to the T4 fibritin trimerization domain (F) and the autochthonus transmembrane domain (TM). Construct (1) starts with the SARS-CoV-2-S signal peptide (SP; AA 1-19 of the S protein) whereas construct (2) starts with the human Ig heavy chain signal peptide (huSec) to ensure Golgi transport to the cell membrane.

[0143] Figure 7. Anti-S protein IgG response 6, 14 and 21 d after immunization with LNP-C12 formulated modRNA coding for transmembrane-anchored RBD-based vaccine constructs.

[0144] BALB / c mice were immunized IM once with 4 μg of LNP-C12-formulated transmembrane- anchored RBD-based vaccine constructs (surrogate to BNT162b3c / BNT162b3d). On day 6, 14 and 21 after immunization, animals were bled and the serum samples were analyzed for total amount of anti-Sl (left) and anti-RBD (right) antigen specific immunoglobulin G (IgG) measured via ELISA. For day 6 (1:50), day 14 (1:300) and day 21 (1:900) different serum dilution were included in the graph. One point in the graph stands for one mouse, every mouse sample was measured in duplicates (group size n=8; mean + SEM is included for the groups). Figure 8. Neutralization of SARS-CoV-2 pseudovirus 6, 14 and 21 d after immunization with LNP-C12 formulated modRNA coding for transmembrane-anchored RBD-based vaccine constructs.

[0145] BALB / c mice were immunized IM once with 4 μg of LNP-C12-formulated transmembrane- anchored RBD-based vaccine constructs (surrogate to BNT162b3c / BNT162b3d). On day 6, 14 and 21 after immunization, animals were bled and the sera were tested for SARS CoV-2 pseudovirus neutralization. Graphs depict pVN50serum dilutions (50% reduction of infectious events, compared to positive controls without serum). One point in the graphs stands for one mouse. Every mouse sample was measured in duplicate. Group size n=8. Mean + SEM is shown by horizontal bars with whiskers for each group. LLOQ, lower limit of quantification. ULOQ, upper limit of quantification.

[0146] Fig. 9. 50% pseudovirus neutralization titers (pVNT50) of sera collected 21 days after the second dose and 1 month after the third dose of BNT162b2 against VSV-SARS-CoV-2-S pseudovirus bearing the Wuhan Hu-1 reference or Omicron BA.1 lineage spike protein. N=19-20 sera from immunized subjects collected either 21 days after the second BNT162b2 dose or 1 months after the third BNT162b2 dose were tested. For values below the limit of detection (LOD; 10), LOD / 2 values are plotted. Group GMTs (values above bars) with 95% confidence intervals are shown.

[0147] Fig. 10. CD8+ T cell epitopes in BNT162b2 vaccine remain largely unaffected by Omicron variant mutations. Shown is the number of previously identified MHC-I epitopes affected in various variants of concern (VOCs). Approximately 80% of previously identified CD8+ epitopes are not affected by the mutations in the Omicron BA.1 variant, suggesting that two doses of BNT162b2 may still induce protection against severe disease.

[0148] Fig. 11. Neutralization of Omicron BA.1 after two doses of BNT162b2 and variant specific booster. Shown is neutralization of the Omicron BA.1 variant from sera of patients administered two doses of BNT162b2 and (i) a third booster dose of BNT162b2, or (ii) a third booster dose of an RNA encoding a Spike protein with alpha or delta variant mutations, or a third booster dose of both a Spike protein comprising alpha mutations and a Spike protein comprising delta mutations. The values are derived from separate neutralization GMTs from the pseudovirus testing. Also shown is a schematic depicting a process for developing new SARS-CoV-2 variant specific vaccines.

[0149] Fig. 12. Longitudinal analysis of neutralizing antibody responses against VSV-SARS-CoV-2-S pseudovirus bearing the Wuhan or Omicron BA.1 variant spike protein in a subset of study participants. Sera from n=9 participants drawn at 21 days after dose 2, prior to dose 3, 1 month after dose 3 and 3 months after dose 3 were tested. Each serum was tested in duplicate and individual geometric mean 50% pseudovirus neutralizing titers (GMTs) were calculated. For values below the limit of detection (LOD), LOD / 2 values were assigned. Group GMTs (values in table) and 95% confidence intervals per time point are indicated.

[0150] Fig. 13. Analysis of HLA class I T cell epitopes conservation between the Wuhan and

[0151] Omicron BA.1 variants. HLA class I restricted Spike protein epitopes with T cell reactivity identified based on their recognition by CD8+ T cells and reported in IEDB (n=244) are plotted by their position (top row) along the Spike protein (bottom row). Epitope indications are positioned by the amino acid position of the center of the epitope; epitopes conserved in both variants are marked in light gray (n=208); while epitopes spanning an Omicron BA.1 mutation site are marked dark gray (n=36). NTD=N-terminal domain; RBD=Receptor-binding domain; FCS=Furin cleavage site. The S1 and S2 regions of the Spike protein are indicated.

[0152] Fig. 14. Schematics of an exemplary vaccination regimen.

[0153] Fig. 15. Cohorts, sampling and experimental setup for characterization of immune response in Omicron BA.1 breakthrough cases. Blood samples were drawn from four cohorts: Omicron-naive individuals double- or triple-vaccinated with BNT162b2, and individuals double- or triple-vaccinated with BNT162b2 that subsequently had a breakthrough infection with Omicron BA.1.PBMCs and sera were isolated in the Omicron- naive cohorts at the time-points indicated following their most recent vaccination; for convalescent cohorts, the time from their most recent vaccination to Omicron BA.1 infection, and infection to PBMC and serum isolation are indicated (all values specified as median-range). Serum neutralizing capacity was assessed using a pseudovirus and live virus neutralization test; SARS-CoV-2 spike-specific BMEMcells were assessed via a flow cytometry- based B cell phenotyping assay using bulk PBMCs. N / A, not applicable.

[0154] Fig. 16. Omicron BA.1 breakthrough infection in BNT162b2 double- and triple-vaccinated individuals induces broad neutralization of Omicron BA.1, BA.2 and other VOCs.

[0155] Serum was drawn from double-vaccinated individuals (BNT162b22) at 22 days after the second dose (open circles), from triple-vaccinated individuals (BNT162b23) at 28 days after the third dose (closed circles), from double-vaccinated individuals with an Omicron BA.1 breakthrough infection (BNT162b22+ Omi) at 46 days post-infection (open triangles), and from triple-vaccinated individuals and Omicron BA.1 breakthrough infection (BNT162b23+ Omi) at 44 days post-infection (closed triangles). Serum was tested in duplicate; (A) shows 50% pseudovirus neutralization (pVN50) geometric mean titers (GMTs), (B) shows 50% virus neutralization (VN50) GMTs, and (C) shows the geometric mean ratio of SARS-CoV-2 variant of concern (VOC) and Wuhan VNso GMTs. For titer values below the limit of detection (LOD), LOD / 2 values were plotted. Values above violin plots represent group GMTs. The non- parametric Friedman test with Dunn's multiple comparisons correction was used to compare Wuhan neutralizing group GMTs with titers against the indicated variants and SARS-CoV-1. Multiplicity-adjusted p values are shown. (A) pVN50GMTs against Wuhan, VOC and SARS- CoV-1 pseudovirus. (B) VNso GMTs against live SARS-CoV-2 Wuhan, Beta, Delta and Omicron BA.1. (C) Group geometric mean ratios with 95% confidence intervals for all cohorts shown in (B).

[0156] Fig. 17. BMEMcells of individuals double- and triple-vaccinated with BNT162b2 broadly recognize VOCs and are further boosted by Omicron BA.1 breakthrough infection. PBMC samples from double-vaccinated individuals (BNT162b22) at 22 days after the second dose (open squares) and 5 months after the second dose (open circles), from triple-vaccinated individuals (BNT162b23) at 84 days after the third dose (closed circles), from double- vaccinated individuals with Omicron BA.1 breakthrough infection (BNT162b22+ Omi) at 46 days post-infection (open triangles), and from triple-vaccinated individuals with Omicron BA.1 breakthrough infection (BNT162b23 + Omi) at 44 days post-infection (closed triangles) were analyzed via flow cytometry for SARS-CoV-2-specific BMEMcell (BMEM- CD3-CD19+CD20+lgD- CD38int / low) frequencies via B cell bait staining. (A) Schematic of one-dimensional staining of BMEMcells with fluorochrome-labeled SARS-CoV-2 S protein tetramer bait allowing discrimination of variant recognition. Frequencies of Wuhan or VOC full-length S protein- (B) and RBD- (C) specific BMEMcells for the four groups of individuals were analyzed. Variant- specific BMEMcell frequencies were normalized to Wuhan frequencies for S protein (D) and RBD- (E) binding. (F) Depicts the frequency ratios of RBD protein specific BMEMcells over full- length S protein-specific BMEMcells.

[0157] Fig. 18. Omicron BA.1 breakthrough infection of BNT162b2 double- and triple-vaccinated individuals primarily boosts BMEMagainst conserved epitopes shared broadly between S proteins of Wuhan and other VOCs rather than strictly Omicron S-specific epitopes. PBMC samples from double-vaccinated individuals (BNT162b22) at 22 days after the second dose (open squares) and 5 months after the second dose (open circles), from triple-vaccinated individuals (BNT162b23) at 84 days after the third dose (closed circles), from double- vaccinated individuals with Omicron BA.1 breakthrough infection (BNT162b22+ Omi) at 46 days post-infection (open triangles), and from triple-vaccinated individuals with Omicron BA.1 breakthrough infection (BNT162b23+ Omi) at 44 days post-infection (closed triangles) were analyzed via flow cytometry for SARS-CoV-2-specific memory B cell (BMEM- CD3- CD19+CD20+lgD-CD38int / low) frequencies via B cell bait staining (schematic shown in (A)). (B) shows representative flow plots of Omicron BA.1 and Wuhan S protein- and RBD-binding for each of the four groups of individuals investigated. Frequencies of BMEMbinding Omicron BA.1, Wuhan, or both (shared) shown for full-length S protein in (C) and RBD shown in (D) for Omicron BA.1-experienced and naive BNT162b2 double and triple vaccinees. (E) Venn diagrams visualizing the combinatorial (Boolean) gating strategy to identify cross-reactive

[0158] BMEMrecognizing all four variants simultaneously (All 4 +ve) and BMEMrecognizing only Omicron BA.1 (only Omi) or only Wuhan (only Wuhan) S proteins. Frequencies for these three

[0159] BMEMsub-groups were compared for full-length S protein (F) and RBD (G) in the four different groups of individuals investigated. RBD variant recognition pattern by BMEMwas assessed through Boolean flow cytometric gating strategy and frequencies recognizing combinations of Wuhan and / or variant RBDs are displayed in (H), for all Omicron convalescent subjects (double and triple vaccinees pooled, n=13). (I) Conserved site within the RBD domain recognized by RBD-specific BMEMafter Omicron BA.1 break-through infection. Mean values are indicated in C, D, F, and G. n = number of individuals per group. Fig. 19. Omicron BA.1 breakthrough infection of individuals vaccinated with other approved COVID-19 vaccines or mixed regimens results in immune sera that broadly neutralize Omicron BA.1, BA.2 and other VOCs plus SARS-CoV-1. Serum was drawn from 10 individuals vaccinated with other approved COVID-19 vaccines or mixed regimens at a median of 43 days after infection (grey diamonds). Serum was tested in duplicate; individual 50% pseudovirus neutralization (pVN50) geometric mean titers (GMTs) against SARS-CoV-2 Wuhan, Alpha, Beta, Delta and Omicron BA.1 and BA.2 variants, plus SARS-CoV-1 were plotted. For titer values below the limit of detection (LOD), LOD / 2 values were plotted. Values above violin plots represent group GMTs. The non-parametric Friedman test with Dunn's multiple comparisons correction was used to compare Wuhan neutralizing group GMTs with titers against the indicated variants and SARS-CoV-1. Multiplicity-adjusted p values are shown. Approved vaccines included AZD1222, BNT162b2 (in some embodiments as part of a 4-dose series), Ad26.COV2.S, mRNA-1273 (administered as a two-dose or three-dose series), and combinations thereof.

[0160] Fig. 20. 50% neutralization titers of sera collected 1 month after a fourth dose of BNT162b2 or an Omicron-specific booster. Subjects who were previously administered two doses of BNT162b2, and a third (booster) dose of BNT162b2 (30 ug) received a dose (30 ug) of (i) an RNA encoding a SARS-CoV-2 S protein from an Omicron BA.1 variant (e.g., as described herein (referred to herein as "Omicron-specific RNA vaccine"), or (ii) BNT162b2, as a fourth (boster) dose. Sera from the subjects were collected one month after administration of the 4th (booster) dose. Group GMTs (values above bars) with 95% confidence intervals are shown. "b2" refers to sera from subjects administered Wuhan-specific RNA vaccine as the 4th(booster) dose of BNT162b2. "OMI" refers to sera from subjects administered an Omicron BA.1-specific 4th(booster) dose. Also shown is the fold-change in titer from before administration of the 4thdose to after administration of the 4thdose (Pre / Post Vax Fold-Rise), and the ratio of geometric mean ratio (GMR) and geometric mean fold rise (GMFR) observed in subjects administered a 4thdose of an Omicron BA.1-specific RNA vaccine as the 4thdose, as compared to subjects administered BNT162b2 as the 4thdose of an Omicron BA.1-specific RNA vaccine. "FFRNT" refers to fluorescent focus reduction neutralization test. Neutralization data was obtained using an FFRNT assay, with a viral particle containing a SARS-CoV-2 S protein from the variant indicated in the figures. (A) Comparison of titers of neutralizing antibodies against a SARS-CoV-2-S pseudovirus comprising a SARS-CoV-2 S protein having mutations characteristics of an Omicron BA.1 variant. Sera from subjects previously or currently infected with SARS-CoV-2 excluded. (B) Comparison of titers of neutralizing antibodies against a SARS- CoV-2 pseudovirus comprising a SARS-CoV-2 S protein having mutations characteristics of an Omicron BA.1 variant in sera from a population that includes subjects previously or currently infected with SARS-CoV-2 (as determined by an antigen assay or a PCR assay respectively). (C) Comparison of titers of neutralizing antibodies against a SARS-CoV-2 pseudovirus comprising a SARS-CoV-2 S protein from a Wuhan strain. Sera from subjects previously or currently infected with SARS-CoV-2 excluded. (D) Comparison of titers of neutralizing antibodies against a SARS-CoV-2 pseudovirus comprising a SARS-CoV-2 S protein from a Wuhan strain, in sera from a population comprising individuals previously or currently infected with SARS-CoV- 2 (as determined by an antigen assay or a PCR assay, respectively. (E) Comparison of titers of neutralizing antibodies against a SARS-CoV-2 pseudovirus comprising a SARS-CoV-2 S protein having mutations characteristics of a delta variant. Sera from subjects previously or currently infected with SARS-CoV-2 excluded. (F) Comparison of titers of neutralization antibodies against a SARS-CoV-2 pseudovirus comprising a SARS-CoV-2 protein having mutations characteristic of a delta variant, in sera from a population including subjects previously or currently infected with SARS-CoV-2 (as determined by an antigen assay or a PCR assay, respectively).

[0161] Fig. 21. Neutralization of SARS-CoV-2 pseudovirus 7 days after immunization with modRNA coding for variant specific S proteins. Mice were immunized twice with LNP-formulated vaccine comprising (i) BNT162b2 (encoding a SARS-CoV-2 S protein from a Wuhan strain), (ii) RNA encoding a SARS-CoV-2 S protein having mutations characteristic of an Omicron BA.1 variant (Omi), (iii) RNA encoding an S protein having mutations characteristic of a delta variant, (iv) a combination of BNT162b2 and an RNA encoding an protein having mutations characteristic of an Omicron BA.1 variant (B2+0mi), or (v) RNA encoding a SARS-CoV-2 S protein having mutations characteristic of a delta variant and RNA encoding a SARS-CoV-2 S protein having mutations characteristic of an Omicron BA.1 variant (Delta + Omi). 7 days after the second immunization, animals were bled and sera was tested for neutralization of a SARS- CoV-2-S pseudovirus comprising a SARS-CoV-2 S protein from a Wuhan strain, or a SARS-CoV- 2 S protein having mutations characteristic of a beta, delta, or Omicron BA.1 variant. Graphs depict pVN50serum dilutions (50% reduction of infectious events, compared to positive controls without serum). One point in the graphs stands for one mouse. Every mouse sample was measured in duplicate. Mean + SEM is shown by horizontal bars with whiskers for each group. LLOD, lower limit of detection. ULOD, upper limit of detection.

[0162] Fig. 22. RNA encoding a SARS-CoV-2 S protein having mutations characteristic of a Beta variant increases neutralization antibody titers against SARS-CoV-2 when administered to patients previously administered two doses of a vaccine encoding a SARS-CoV-2 S protein of a Wuhan strain. Subjects previously administered two doses of an RNA vaccine encoding a SARS-CoV-2 S protein of a Wuhan strain were administered a third and a fourth dose of an RNA vaccine encoding a SARS-CoV-2 S protein having mutations characteristic of a Beta variant. Neutralization antibody titers were measured before administration of an RNA vaccine encoding a SARS-CoV-2 S protein of a Wuhan strain (Dl-PreVax), one month after administration of a second dose of an RNA vaccine encoding a SARS-CoV-2 S protein of a Wuhan strain (M1PD2), one-month after administration of a third dose of an RNA vaccine encoding a SARS-CoV-2 S protein having mutations characteristic of a SARS-CoV-2 Beta variant, and one month after administration of a fourth dose of an RNA vaccine encoding a SARS-CoV- 2 S protein having mutations characteristic of a SARS-CoV-2 Beta variant. The third and fourth doses were administered 1 month apart from one another. GMFR refers to the geometric mean fold rise, and is a measure of the increase in neutralization antibody titers since the previous vaccine dose (e.g., the GMFR for Post-Dose2 (PD2) is a measure of the increase in neutralization antibody titers relative to before administration of any vaccine (pre-vax)). (A) Neutralization antibody titers measured in a viral neutralization assay that uses a viral particle comprising a SARS-CoV-2 S protein of a Wuhan strain. (B) Neutralization antibody titers measured in a viral neutralization assay that uses a viral particle comprising a SARS-CoV-2 S protein having mutations characteristic of a Beta variant.

[0163] Fig. 23. 50% neutralization titers of sera collected 7 days after a fourth dose of BNT162b2, an Omicron BA.1-specific booster, or a bivalent vaccine. Subjects who were previously administered two doses of BNT162b2 (30 ug), and a third (booster) dose of BNT162b2 (30 ug) received (i) a 30 ug dose of BNT162b2 (encoding a SARS-CoV-2 S protein from a Wuhan strain), (ii) a 60 ug dose of BNT162b2, (iii) a 30 ug dose of RNA encoding a SARS-CoV-2 S protein having mutations characteristic of an Omicron BA.1 variant (e.g., as described herein (referred to herein as "Omicron-specific RNA vaccine")), (iii) a 60 ug dose of RNA encoding a SARS-CoV-2 S protein having mutations characteristic of an Omicron BA.1 variant, (iv) a 30 ug dose of a bivalent vaccine, comprising 15 ug of BNT162b2 and 15 ug of RNA encoding a SARS-CoV-2 S protein comprising mutations characteristic of an Omicron BA.1 variant, or (v) a 60 ug dose of a bivalent vaccine, comprising 30 ug of BNT162b2 and 30 ug of RNA encoding a SARS-CoV-2 S protein comprising mutations characteristic of an Omicron BA.1 variant. Geometric mean ratio (GMR) of titers in serum from subjects were collected 7 days after administration of a 4th dose. "b2" refers to sera from subjects administered a Wuhan-specific RNA vaccine as a 4thdose of BNT162b2. "OMI" refers to sera from subjects administered an Omicron BA.1-specific 4thdose. "Bivalent" refers to sera from subjects administered a composition comprising BNT162b2 and an RNA encoding a SARS-CoV-2 S protein comprising mutations that are characteristic of an Omicron BA.1 variant as a 4thdose. Also shown is the fold-rise in titer from before administration of a 4thdose to 7 days after administration of a 4thdose (*Fold-Rise). "FFRNT" refers to fluorescent focus reduction neutralization test. Neutralization data was obtained using an FFRNT assay, with a viral particle containing a SARS-CoV-2 S protein having mutations characteristic of the variant indicated in the figures. LLOQ refers to Lower Limit of Quantification and ULOQ refers to Upper Limit of Quantification. (A) Comparison of titers of neutralizing antibodies against a SARS-CoV-2 pseudovirus comprising a SARS-CoV-2 S protein having mutations characteristics of an Omicron BA.1 variant. Sera from subjects previously or currently infected with SARS-CoV-2 excluded. (B) Comparison of titers of neutralizing antibodies against a SARS-CoV-2 pseudovirus comprising a SARS-CoV-2 S protein having mutations characteristics of an Omicron BA.1 variant in sera from a population that includes subjects previously or currently infected with SARS-CoV-2 (e.g., as determined by an antibody test or a PCR assay respectively). (C) Comparison of titers of neutralizing antibodies against a SARS-CoV-2 pseudovirus comprising a SARS-CoV-2 S protein of a Wuhan strain. Sera from subjects previously or currently infected with SARS-CoV-2 excluded. (D) Comparison of titers of neutralizing antibodies against a SARS-CoV-2 pseudovirus comprising a SARS-CoV-2 S protein of a Wuhan strain, in sera from a population that includes individuals previously or currently infected with SARS-CoV-2. (E) Comparison of titers of neutralizing antibodies against a SARS-CoV-2 pseudovirus comprising a SARS-CoV-2 S protein having mutations characteristics of a Delta variant. Sera from subjects previously or currently infected with SARS-CoV-2 excluded. (F) Comparison of titers of neutralization antibodies against a SARS-CoV-2 pseudovirus comprising a SARS-CoV-2 S protein having mutations characteristic of a Delta variant, in sera from a population including subjects previously or currently infected with SARS-CoV-2. (G) Geometric mean rise (GMR) of neutralization antibodies observed in subjects administered 60 ug of BNT162b2, 30 ug of RNA encoding a SARS-CoV-2 S protein having mutations characteristic of an Omicron BA.1 variant (OMI 30 ug), 60 ug of RNA encoding a SARS-CoV-2 S protein having mutations characteristic of an Omicron BA.1 variant (OMI 60 ug), 30 ug of a bivalent vaccine comprising 15 ug of BNT162b2 and 15 ug of RNA encoding a SARS- CoV-2 S protein having mutations characteristic of an Omicron BA.1 variant (Bivalent 30 ug), or 60 ug of a bivalent vaccine comprising 30 ug of BNT162b2 and 30 ug of RNA encoding a SARS-CoV-2 S protein having mutations characteristic of an Omicron BA.1 variant (Bivalent 60 ug), as compared to subjects administered 30 ug of BNT162b2 as a 4thdose. Results are shown both for a population pool that excludes subjects previously or currently infected with SARS- CoV-2 and a population pool that includes these subjects.

[0164] Fig. 24. Reactogenicity of certain exemplary RNA (formulated in LNP) at a given dose: subjects administered a 60 ug dose of RNA encoding a SARS-CoV-2 S protein are more likely to exhibit a higher injection site pain and exhibit similar systemic reactions as subjects administered a 30 ug dose of RNA. Subjects were administered 30 ug or 60 ug of RNA encoding a SARS-CoV-2 S protein from a Wuhan strain (BNT162b2, corresponding to groups G1 and G2, respectively), 30 ug or 60 ug of RNA encoding a SARS-CoV-2 S protein having mutations characteristic of an Omicron BA.1 variant (BNT162b2 OMI, corresponding to groups G3 and G4, respectively), 30 ug of a bivalent vaccine comprising 15 ug of RNA encoding a SARS- CoV-2 S protein from a Wuhan strain and 15 ug of RNA encoding a SARS-CoV-2 S protein having mutations characteristic of an Omicron BA.1 variant (BNT162B2 (15 ug) + BNT162b2 OMI (15 ug), corresponding to group G5), or 60 ug of a bivalent vaccine comprising 30 ug of RNA encoding a SARS-CoV-2 S protein from a Wuhan strain and 30 ug of RNA encoding a SARS-CoV- 2 S protein having mutations characteristic of an Omicron BA.1 variant (BNT162b2 (30 ug) + BNT162b2 OMI (30 ug), corresponding to group G6). (A) Local reactions, including redness, swelling, and pain at the injection site, observed within 7 days of injection. Injection site pain was found to be increased in subjects administered 60 ug of RNA encoding a SARS-CoV-2 S protein comprising mutations characteristic an Omicron BA.1 variant or a bivalent vaccine, as compared to other doses tested. (B) Systemic reactions, including fever, fatigue, headache, chills, vomiting, diarrhea, muscle pain, joint pain, and use of medication, observed within 7 days of injection. Systemic reactions through 7 days were observed to be broadly similar across different groups. Fatigue was found to trend higher after administration of 60 ug doses, as compared to 30 ug doses.

[0165] Fig. 25. Omicron BA.1 breakthrough infection of BNT162b2 double- and triple-vaccinated individuals induces broad neutralization of Omicron BA.1, BA.2 and other VOCs, but to a lesser extent against BA.4 and BA.5. This figure is an extension of Fig. 16, including data neutralizing activity against Omicron BA.4 and BA.5. As described in Fig. 16, serum was tested in duplicate; 50% pseudovirus neutralization (pVN50) geometric mean titers (GMTs) (in A and B), and the geometric mean ratio of SARS-CoV-2 variants of concern (VOCs) and SARS- CoV-1 pVN50GMTs normalized against Wuhan pVN50GMTs (in C) were plotted. For titer values below the limit of detection (LOD), LOD / 2 values were plotted. Values above violin plots represent the group GMTs. The nonparametric Friedman test with Dunn's multiple comparisons correction was used to compare Wuhan neutralizing group GMTs with titers against the indicated variants and SARS-CoV-1. Multiplicity adjusted p values are shown. (A) pVN so GMTs against Wuhan, VOC and SARS-CoV-1 pseudovirus in patients who received two doses or three doses of BNT162b2. (B) pVN50GMTs against Wuhan, VOC and SARS-CoV-1 pseudovirus in patients who received two doses or three doses of BNT162b2 and who have been previously infected with an Omicron BA.1 variant of SARS-CoV-2. (C) Group geometric mean ratios with 95% confidence intervals for all cohorts shown in (A) and (B).

[0166] Fig. 26. Omicron BA.1 breakthrough infection of individuals vaccinated with other approved COVID-19 vaccines or mixed regimens results in immune sera that broadly neutralize Omicron BA.1, BA.2 and other VOCs, but to a lesser extent against BA.4 and BA.5.

[0167] This figure is an extension of Fig. 19, including data neutralizing activity against Omicron BA.4 and BA.5. As described in Fig. 19, serum was tested in duplicate; individual 50% pseudovirus neutralization (pVN50) geometric mean titers (GMTs) against SARS-CoV-2 Wuhan, Alpha, Beta, Delta and Omicron BA.1, BA.2 and BA.4 / 5 variants, plus SARS-CoV-1 were plotted. For titer values below the limit of detection (LOD), LOD / 2 values were plotted. Values above violin plots represent group GMTs. The nonparametric Friedman test with Dunn's multiple comparisons correction was used to compare Wuhan neutralizing group GMTs with titers against the indicated variants and SARS-CoV-1. Multiplicity-adjusted p values are shown.

[0168] Fig. 27. Sequences of RBDs of SARS-COV-2 Wuhan strain and variants thereof. Top sequence corresponds to Wuhan, second sequence corresponds to the Alpha variant, third sequence corresponds to the Delta variant, 4thsequence corresponds to Omicron BA.1 variant, and 5thsequence corresponds to Omicron BA.4 / 5 variant. Variant-specific amino acid alterations are indicated in bold.

[0169] Fig. 28. Cohorts and sampling for the study described in Example 14. A schematic is shown for testing immune responses in triple-vaccinated patients who are (i) Omicron naive, (ii) have been infected with a BA.1 Omicron variant, or (iii) have been infected with a BA.2 Omicron variant. Blood samples were drawn from three cohorts: Omicron-naive individuals triple- vaccinated with BNT162b2 (BNT162b23), and individuals vaccinated with homologous or heterologous three doses regimens that subsequently had either a breakthrough infection with Omicron at a time of BA.1 dominance (November 2021 to January 2022; all Vax + BA.1) or at a time of BA.2 dominance (March to May 2022; all Vax + BA.2) in Germany. Sera (droplet) were isolated in the Omicron-naive cohort at the time-point indicated following their most recent vaccination; for convalescent cohorts, the time from their most recent vaccination to Omicron infection, and infection to serum isolation are indicated. All values specified as median-range. Serum neutralizing capacity was assessed using a pseudovirus neutralization test.

[0170] Fig. 29. 50% pseudovirus neutralization (pVN50) geometric mean titers (GMTs) from the BNT162b23and All Vax + Omi BA.1 breakthrough infection cohorts. Serum was drawn from Omicron-naive BNT162b2 triple-vaccinated individuals (BNT162b23, circles) at 28 days after the third dose, and from vaccinated individuals with subsequent Omicron BA.1 breakthrough infection (all Vax + Omi BA.1, triangles) at a median 43 days post-infection. 50% pseudovirus neutralization (pVN50) geometric mean titers (GMTs) for Omicron-naive individuals are plotted in (A) and for BA.1 breakthrough infected individuals in (B). This data was previously published in Quandt et al. („Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes." Science immunology, eabq2427 (2022), doi:10.1126 / sciimmunol.abq2427), except for BA.2.12.1 neutralization data. Serum was tested in duplicate. For titer values below the limit of detection (LOD), LOD / 2 values were plotted. Values above violin plots represent group GMTs. The non-parametric Friedman test with Dunn's multiple comparisons correction was used to compare Wuhan neutralizing group GMTs with titers against the indicated variants and SARS-CoV-1. Multiplicity-adjusted p values are shown.

[0171] Fig. 30. Omicron BA.2 breakthrough infection of previously vaccinated individuals refocuses neutralization against Omicron BA.2 and the BA.2-derived subvariants BA.2.12.1 and BA.4 / BA.5. Serum was drawn from BNT162b2 triple-vaccinated individuals with subsequent Omicron BA.1 breakthrough infection at a median 44 days post-infection (BNT162b23+ Omi BA.1, triangles), and from BNT162b2 triple-vaccinated individuals with subsequent Omicron BA.2 breakthrough infection at 38 days post-infection (BNT162b23+ Omi BA.2, squares). 50% pseudovirus neutralization (pVN50) geometric mean titers (GMTs) (in A, B), and the geometric mean ratio of SARS-CoV-2 variants of concern (VOCs) and SARS-CoV-1 pVN50GMTs normalized against Wuhan pVN50 GMTs (in C) were plotted. pVN50GMT and geometric mean ratio data for Omicron-naive BNT162b2 triple-vaccinated individuals (BNT162b23, circles) and BNT162b2 triple-vaccinated individuals with Omicron BA.1 breakthrough infection was previously published in Quandt et al. („Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes." Science immunology, eabq2427 (2022), doi:10.1126 / sciimmunol.abq2427), except for BA.2.12.1 neutralization data. Serum was tested in duplicate. For titer values below the limit of detection (LOD), LOD / 2 values were plotted. Values above violin plots represent group GMTs. The non- parametric Friedman test with Dunn's multiple comparisons correction was used to compare Wuhan neutralizing group GMTs with titers against the indicated variants and SARS-CoV-1. Multiplicity-adjusted p values are shown. (A, B) pVN50GMTs against Wuhan, VOC and SARS- CoV-1 pseudovirus. (C) Group geometric mean ratios with 95% confidence intervals.

[0172] Fig. 31. Characteristics of SARS-CoV-2 S glycoproteins used in the VSV-SARS-CoV-2 pseudovirus based neutralization assays. The sequence of the Wuhan-Hu-1 isolate SARS-CoV- 2 S glycoprotein (GenBank: QHD43416.1) was used as reference. Amino acid positions, amino acid descriptions (one letter code) and kind of mutations (substitutions, deletions, insertions) are indicated. NTD, N-terminal domain; RBD, Receptor-binding domain, A, deletion; ins, insertion; *, Cytoplasmic domain truncated for the C-terminal 19 amino acids.

[0173] Fig. 32. Alterations on the spike glycoprotein amino acid sequence of SARS-CoV-2 Omicron sub-lineages. Amino acid positions, amino acid descriptions (one letter code) and kind of mutations substitutions, deletions, insertions) are indicated. White letters in boxes indicate the amino acid substitution per sub-lineage; A, deletion; ins, insertion; NTD, N-terminal domain; RBD, receptor-binding domain.

[0174] Fig. 33. Immunization protocol for studies with VOC boosters. BALB / c mice were immunized according to the indicated schedule with two doses (1 ug each) of the original BNT162b2 vaccine, followed by at least one dose (1 ug total) of a monovalent, bivalent, or trivalent booster dose of either: (a) the original BNT162b2 ("BNT162b2"); (b) BNT162b2 OMI BA.1 ("OMI BA.1"); (c) BNT162b2 OMI BA.4 / 5 ("OMI BA.4 / 5"); or a combination thereof.

[0175] Fig. 34. Baseline grouped neutralizing GMTs. Sera drawn from mice immunized as depicted in Fig. 33 (day 104, pre-boost) were assessed for geometric mean titers of neutralizing antibodies against various strains. Data are presented grouped by cohort.

[0176] Fig. 35. Baseline staggered neutralizing GMTs. Sera drawn from mice immunized as depicted in Fig. 33 (day 104, pre-boost) were assessed for geometric mean titers of neutralizing antibodies against various strains. Data are presented in staggered format (i.e., by strain against which neutralization was assessed).

[0177] Fig. 36. Baseline cross-neutralization. Sera drawn from mice immunized as depicted in Fig. 33 (day 104, pre-boost) were assessed for geometric mean titers of neutralizing antibodies against various strains. Cross-neutralization results are presented as calculated variant / Wuhan reference GMT Ratios. Fig. 37. Post-boost geometric mean fold increase in GMTs. Sera drawn from mice immunized as depicted in Fig. 33 (day 111, 7-days post-boost) were assessed for geometric mean fold increase in GMT of neutralizing antibodies against various strains.

[0178] Fig. 38. Post-boost grouped neutralizing GMTs. Sera drawn from mice immunized as depicted in Fig. 33 (day 111, 7-days post-boost) were assessed for geometric mean fold increase in GMT of neutralizing antibodies against various strains. Data are presented grouped by cohort.

[0179] Fig. 39. Post-boost cross-neutralization. Sera drawn from mice immunized as depicted in Fig. 33 (day 111, 7-days post-boost) were assessed for geometric mean fold increase in GMT of neutralizing antibodies against various strains. Cross-neutralization results are presented as calculated variant / Wuhan reference GMT Ratios.

[0180] Fig. 40. Exemplary spike protein amino acid mutations. Amino acid residues that are modified are shown, and used to produce RNA vaccines encoding variant coronavirus spike proteins. In some instances, such amino acid modifications can be combined with otheramino acid residue modifications, such as as shown in Fig. 41 under columns "Mutations" and "Mutation Types". The amino acid positions are numbered relative to the S protein sequence from a Wuhan sequence (SEQ ID NO: 1). In some embodiments, various combinations of amino acid mutations as described herein can be applied to different coronvavirus S protein or immunogenic fragments thereof.

[0181] Fig. 41. Exemplary Spike Protein Variants. Exemplary combinations of spike protein mutations are shown, including the amino acid residues that are modified, type of mutation, and furin mutations (from 682 / 683 / 684 / 685 RRAR to GSAS). RNA constructs encoding exemplary combinations of spike protein mutations were evaluated for S protein expression, CR3022 epitope response, and ACE2 response. The amino acid positions are numbered relative to the S protein sequence from a Wuhan sequence (SEQ ID NO: 1). In some embodiments, various combinations of amino acid mutations as described herein can be applied to different coronvavirus S protein or immunogenic fragments thereof. Fig. 42. Effect of RNA encoding exemplary spike protein variants on neutralization against various coronavirvus strains and / or variants. RNAs encoding exemplary spike protein variants (e.g., containing a P6' backbone as shown in Fig. 40, D614G, and furin site mutations (from 682 / 683 / 684 / 685 RRAR to GSAS)) stimulated higher neutralization titers across various VOCs.

[0182] Fig. 43. BNT162b5-format Bivalent (Wuhan + BA.4 / 5) is more immunogenic than BNT162b2- format Bivalent (Wuhan + BA.4 / 5). Mice were administered two doses of BNT162b2 21 days apart, followed by a third dose comprising (i) BNT162b2, (ii) a bivalent vaccine comprising a first RNA encoding a Wuhan Spike protein and a second RNA encoding a SARS-CoV-2 Spike protein comprising mutations characteristic of a BA.4 / 5 Omicron variant, where the Spike protein encoded by each of the first and the second RNA also comprise K986P and V987P mutations ("BNT162b2 Bivalent (BA.4 / 5)"), or (iii) a bivalent vaccine comprising a first RNA encoding a Wuhan Spike protein and a second RNA encoding a SARS-CoV-2 Spike protein comprising mutations characteristic of a BA.4 / 5 Omicron variant, where the S protein encoded by each of the first and the second RNA also comprise P6' mutations (D985P, V987P, F817P, A892P, A899P, and A942P), D614G, and mutations at the furin cleavage site (682 / 683 / 684 / 685 RRAR to GSAS) ("BNT162b5 Bivalent (BA.4 / 5)"). Sera samples were collected 1 month after the third dose, and neutralization titers were determined for Wuhan and Omicron variants BA.1, BA.2, BA.2.12.1, and BA.4 / 5 using a pseudovirus neutralization assay (50% pVNT Titers).

[0183] Fig. 44. Bivalent BNT162b5 provides an improved immune response in vaccine-experienced human subjects. Human subjects previously administered three doses of BNT162b2 (encoding a SARS-CoV-2 S protein of a Wuhan strain, and comprising K986P and V987P mutations) were administered (i) a bivalent vaccine comprising a first RNA encoding a Wuhan Spike protein and a second RNA encoding a SARS-CoV-2 Spike protein comprising mutations characteristic of a BA.1 Omicron variant, where the Spike protein encoded by each of the first and the second RNA also comprise K986P and V987P mutations ("BNT162b2 Bivalent Omi BA.1"), or (ii) a bivalent vaccine comprising a first RNA encoding a Wuhan Spike protein and a second RNA encoding a SARS-CoV-2 Spike protein comprising mutations characteristic of a BA.2 Omicron variant, where the S protein encoded by each of the first and the second RNA also comprise P6' mutations (D985P, V987P, F817P, A892P, A899P, and A942P), D614G, and mutations at the furin cleavage site (682 / 683 / 684 / 685 RRAR to GSAS) ("BNT162b5 Bivalent (BA.2)"). Sera were collected one month after administering an RNA vaccine, and neutralization titers were collected for Wuhan ("WT"), Omicron BA.1 ("BA.1"), or Omicron BA.2 ("BA.2") SARS-COV-2 variants. Titers are shown for (A) all subjects, (B) subjects who showed evidence of prior SARS-CoV-2 infection at the time a SARS-CoV-2 vaccine was administered, and (C) subjects who showed no evidence of prior SARS-CoV-2 infection at the time of administering a SARS-CoV-2 vaccine. Titer values are shown above each bar. Titers were collected using a Fluroscent Focus Reduction Neutralization Titer (FFRNT) assay. "1MPD4" refers to one-month, post dose 4. "WT" refers to Wuhan strain. "LLOQ" stands for Lower Limit of Quantitation.

[0184] Fig. 45. Bivalent BNT162b5 and BNT162b6 provide an improved immune response when administered as a booster to vaccine-experienced mice. Mice administered two doses of BNT162b2 (encoding a SARS-CoV-2 S protein of a Wuhan strain, and comprising K986P and V987P mutations) were administered (i) a bivalent vaccine comprising a first RNA encoding a Wuhan Spike protein and a second RNA encoding a SARS-CoV-2 Spike protein comprising mutations characteristic of a BA.4 / 5 Omicron variant, where the Spike protein encoded by each of the first and the second RNA also comprise K986P and V987P mutations ("BNT162b2 Bivalent BA.4 / 5"), (ii) a bivalent vaccine comprising a first RNA encoding a Wuhan Spike protein and a second RNA encoding a SARS-CoV-2 Spike protein comprising mutations characteristic of a BA.4 / 5 Omicron variant, where the S protein encoded by each of the first and the second RNA also comprise P6' mutations (D985P, V987P, F817P, A892P, A899P, and A942P), D614G, and mutations at the furin cleavage site (682 / 683 / 684 / 685 RRAR to GSAS) ("BNT162b5 Bivalent (BA.4 / 5)"), or (iii) a bivalent vaccine comprising a first RNA encoding a Wuhan Spike protein and a second RNA encoding a SARS-CoV-2 Spike protein comprising mutations characteristic of a BA.4 / 5 Omicron variant, where the S protein encoded by each of the first and the second RNA also comprise P6 mutations (K986P, V987P, F817P, A892P, A899P, and A942P), D614G, mutations at the furin cleavage site (682 / 683 / 684 / 685 RRAR to GSAS), and mutations to introduce a disulfide bond (T547C, N978C) ("BNT162b6 Bivalent (BA.4 / 5)"). Sera were collected one month after administering an RNA vaccine, and neutralization titers were deteremined for a collection of variants of concern (indicated in the legend). 50% neutralization titers ("50% pVNT Titer") are shown. "LOD" stands for Limit of

[0185] Detection.

[0186] Fig. 46. In vitro characterization of Exemplary SARS-CoV-2 Variants. Shown is protein expression, ACE2 binding, and CR3022 binding (a neutralizing antibody) for certain exemplary SARS-CoV-2 variants comprising mutations described herein (mutations present in each SARS- CoV-2 variant listed in Table 34).

[0187] Fig. 47. In vitro characterization of Exemplary SARS-CoV-2 Variants. Shown is protein expression, ACE2 binding, and CR3022 binding (a neutralizing antibody) for certain exemplary SARS-CoV-2 variants comprising mutations described herein (mutations present in each SARS- CoV-2 variant listed in Table 34).

[0188] Fig. 45. Bivalent BNT162b6, and BNT162b7 provide an improved immune response when administered as a booster to vaccine-naive mice. Mice were administered (i) a bivalent vaccine comprising a first RNA encoding a Wuhan Spike protein and a second RNA encoding a SARS-CoV-2 Spike protein comprising mutations characteristic of a BA.4 / 5 Omicron variant, where the Spike protein encoded by each of the first and the second RNA also comprise K986P and V987P mutations ("BNT162b2 Bivalent BA.4 / 5"), (ii) a bivalent vaccine comprising a first RNA encoding a Wuhan Spike protein and a second RNA encoding a SARS-CoV-2 Spike protein comprising mutations characteristic of a BA.4 / 5 Omicron variant, where the S protein encoded by each of the first and the second RNA also comprise P6' mutations (D985P, V987P, F817P, A892P, A899P, and A942P), D614G, and mutations at the furin cleavage site (682 / 683 / 684 / 685 RRAR to GSAS) ("BNT162b5 Bivalent (BA.4 / 5)"), (iii) a bivalent vaccine comprising a first RNA encoding a Wuhan Spike protein and a second RNA encoding a SARS-CoV-2 Spike protein comprising mutations characteristic of a BA.4 / 5 Omicron variant, where the S protein encoded by each of the first and the second RNA also comprise P6 mutations (K986P, V987P, F817P, A892P, A899P, and A942P), D614G, mutations at the furin cleavage site (682 / 683 / 684 / 685 RRAR to GSAS), and mutations to introduce a disulfide bond (T547C, N978C) ("BNT162b6 Bivalent (BA.2)"), or (iv) a bivalent vaccine comprising a first RNA encoding a Wuhan Spike protein and a second RNA encoding a SARS-CoV-2 Spike protein comprising mutations characteristic of a BA.4 / 5 Omicron variant, where the S protein encoded by each of the first and the second RNA also comprise P6 mutations (K986P, V987P, F817P, A892P, A899P, and A942P), D614G, mutations at the furin cleavage site (682 / 683 / 684 / 685 RRAR to GSAS), and mutations to introduce a disulfide bond (T547C, S982C) ("BNT162b7 Bivalent (BA.4 / 5)"). Sera were collected one month after administering an RNA vaccine, and neutralization titers were determined for a collection of variants of concern (indicated in the legend). 50% neutralization titers ("50% pVNT Titer") are shown in (A) and (B), and neutralization titers relative to BNT162b2 titers are shown in (C).

[0189] Detailed description

[0190] Although the present disclosure is described in detail below, it is to be understood that this disclosure is not limited to the particular methodologies, protocols and reagents described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present disclosure which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0191] Preferably, the terms used herein are defined as described in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", H.G.W. Leuenberger, B. Nagel, and H. Koi bl, Eds., Helvetica Chimica Acta, CH-4010 Basel, Switzerland, (1995).

[0192] The practice of the present disclosure will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, cell biology, immunology, and recombinant DNA techniques which are explained in the literature in the field (cf., e.g., Molecular Cloning: A Laboratory Manual, 2nd Edition, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989).

[0193] In the following, the elements of the present disclosure will be described. These elements are listed with specific embodiments, however, it should be understood that they may be combined in any manner and in any number to create additional embodiments. The variously described examples and embodiments should not be construed to limit the present disclosure to only the explicitly described embodiments. This description should be understood to disclose and encompass embodiments which combine the explicitly described embodiments with any number of the disclosed elements. Furthermore, any permutations and combinations of all described elements should be considered disclosed by this description unless the context indicates otherwise.

[0194] Several documents are cited throughout the text of this specification. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.), whether supra or infra, are hereby incorporated by reference in their entirety. Nothing herein is to be construed as an admission that the present disclosure was not entitled to antedate such disclosure.

[0195] Definitions

[0196] In the following, definitions will be provided which apply to all aspects of the present disclosure. The following terms have the following meanings unless otherwise indicated. Any undefined terms have their art recognized meanings.

[0197] The term "about" means approximately or nearly, and in the context of a numerical value or range set forth herein in one embodiment means ± 20%, ± 10%, ± 5%, or ± 3% of the numerical value or range recited or claimed.

[0198] The terms "a" and "an" and "the" and similar reference used in the context of describing the disclosure (especially in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it was individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as"), provided herein is intended merely to better illustrate the disclosure and does not pose a limitation on the scope of the claims. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the disclosure.

[0199] Unless expressly specified otherwise, the term "comprising" is used in the context of the present document to indicate that further members may optionally be present in addition to the members of the list introduced by "comprising". It is, however, contemplated as a specific embodiment of the present disclosure that the term "comprising" encompasses the possibility of no further members being present, i.e., for the purpose of this embodiment "comprising" is to be understood as having the meaning of "consisting of" or "consisting essentially of".

[0200] Terms such as "reduce", "decrease", "inhibit" or "impair" as used herein relate to an overall reduction or the ability to cause an overall reduction, preferably of at least 5%, at least 10%, at least 20%, at least 50%, at least 75% or even more, in the level. These terms include a complete or essentially complete inhibition, i.e., a reduction to zero or essentially to zero.

[0201] Terms such as "increase", "enhance" or "exceed" preferably relate to an increase or enhancement by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 80%, at least 100%, at least 200%, at least 500%, or even more.

[0202] According to the disclosure, the term "peptide" comprises oligo- and polypeptides and refers to substances which comprise about two or more, about 3 or more, about 4 or more, about 6 or more, about 8 or more, about 10 or more, about 13 or more, about 16 or more, about 20 or more, and up to about 50, about 100 or about 150, consecutive amino acids linked to one another via peptide bonds. The term "protein" or "polypeptide" refers to large peptides, in particular peptides having at least about 150 amino acids, but the terms "peptide", "protein" and "polypeptide" are used herein usually as synonyms.

[0203] A "therapeutic protein" has a positive or advantageous effect on a condition or disease state of a subject when provided to the subject in a therapeutically effective amount. In one embodiment, a therapeutic protein has curative or palliative properties and may be administered to ameliorate, relieve, alleviate, reverse, delay onset of or lessen the severity of one or more symptoms of a disease or disorder. A therapeutic protein may have prophylactic properties and may be used to delay the onset of a disease or to lessen the severity of such disease or pathological condition. The term "therapeutic protein" includes entire proteins or peptides, and can also refer to therapeutically active fragments thereof. It can also include therapeutically active variants of a protein. Examples of therapeutically active proteins include, but are not limited to, antigens for vaccination and immunostimulants such as cytokines.

[0204] "Fragment", with reference to an amino acid sequence (peptide or protein), relates to a part of an amino acid sequence, i.e. a sequence which represents the amino acid sequence shortened at the N-terminus and / or C-terminus. A fragment shortened at the C-terminus (N- terminal fragment) is obtainable e.g. by translation of a truncated open reading frame that lacks the 3'-end of the open reading frame. A fragment shortened at the N-terminus (C- terminal fragment) is obtainable e.g. by translation of a truncated open reading frame that lacks the 5'-end of the open reading frame, as long as the truncated open reading frame comprises a start codon that serves to initiate translation. A fragment of an amino acid sequence comprises e.g. at least 50 %, at least 60 %, at least 70 %, at least 80%, at least 90% of the amino acid residues from an amino acid sequence. A fragment of an amino acid sequence preferably comprises at least 6, in particular at least 8, at least 12, at least 15, at least 20, at least 30, at least 50, or at least 100 consecutive amino acids from an amino acid sequence.

[0205] By "variant" herein is meant an amino acid sequence that differs from a parent amino acid sequence by virtue of at least one amino acid modification. The parent amino acid sequence may be a naturally occurring or wild type (WT) amino acid sequence, or may be a modified version of a wild type amino acid sequence. Preferably, the variant amino acid sequence has at least one amino acid modification compared to the parent amino acid sequence, e.g., from 1 to about 20 amino acid modifications, and preferably from 1 to about 10 or from 1 to about 5 amino acid modifications compared to the parent.

[0206] By "wild type" or "WT" or "native" herein is meant an amino acid sequence that is found in nature, including allelic variations. A wild type amino acid sequence, peptide or protein has an amino acid sequence that has not been intentionally modified.

[0207] For the purposes of the present disclosure, "variants" of an amino acid sequence (peptide, protein or polypeptide) comprise amino acid insertion variants, amino acid addition variants, amino acid deletion variants and / or amino acid substitution variants. The term "variant" includes all mutants, splice variants, posttranslationally modified variants, conformations, isoforms, allelic variants, species variants, and species homologs, in particular those which are naturally occurring. The term "variant" includes, in particular, fragments of an amino acid sequence.

[0208] Amino acid insertion variants comprise insertions of single or two or more amino acids in a particular amino acid sequence. In the case of amino acid sequence variants having an insertion, one or more amino acid residues are inserted into a particular site in an amino acid sequence, although random insertion with appropriate screening of the resulting product is also possible. Amino acid addition variants comprise amino- and / or carboxy-terminal fusions of one or more amino acids, such as 1, 2, 3, 5, 10, 20, 30, 50, or more amino acids. Amino acid deletion variants are characterized by the removal of one or more amino acids from the sequence, such as by removal of 1, 2, 3, 5, 10, 20, 30, 50, or more amino acids. The deletions may be in any position of the protein. Amino acid deletion variants that comprise the deletion at the N-terminal and / or C-terminal end of the protein are also called N-terminal and / or C- terminal truncation variants. Amino acid substitution variants are characterized by at least one residue in the sequence being removed and another residue being inserted in its place. Preference is given to the modifications being in positions in the amino acid sequence which are not conserved between homologous proteins or peptides and / or to replacing amino acids with other ones having similar properties. Preferably, amino acid changes in peptide and protein variants are conservative amino acid changes, i.e., substitutions of similarly charged or uncharged amino acids. A conservative amino acid change involves substitution of one of a family of amino acids which are related in their side chains. Naturally occurring amino acids are generally divided into four families: acidic (aspartate, glutamate), basic (lysine, arginine, histidine), non-polar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In one embodiment, conservative amino acid substitutions include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

[0209] Preferably the degree of similarity, preferably identity between a given amino acid sequence and an amino acid sequence which is a variant of said given amino acid sequence will be at least about 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. The degree of similarity or identity is given preferably for an amino acid region which is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or about 100% of the entire length of the reference amino acid sequence. For example, if the reference amino acid sequence consists of 200 amino acids, the degree of similarity or identity is given preferably for at least about 20, at least about 40, at least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 amino acids, in some embodiments continuous amino acids. In some embodiments, the degree of similarity or identity is given for the entire length of the reference amino acid sequence. The alignment for determining sequence similarity, preferably sequence identity can be done with art known tools, preferably using the best sequence alignment, for example, using Align, using standard settings, preferably EMBOSS::needle, Matrix: Blosum62, Gap Open 10.0, Gap Extend 0.5.

[0210] "Sequence similarity" indicates the percentage of amino acids that either are identical or that represent conservative amino acid substitutions. "Sequence identity" between two amino acid sequences indicates the percentage of amino acids that are identical between the sequences. "Sequence identity" between two nucleic acid sequences indicates the percentage of nucleotides that are identical between the sequences.

[0211] The terms "% identical", "% identity" or similar terms are intended to refer, in particular, to the percentage of nucleotides or amino acids which are identical in an optimal alignment between the sequences to be compared. Said percentage is purely statistical, and the differences between the two sequences may be but are not necessarily randomly distributed over the entire length of the sequences to be compared. Comparisons of two sequences are usually carried out by comparing the sequences, after optimal alignment, with respect to a segment or "window of comparison", in order to identify local regions of corresponding sequences. The optimal alignment for a comparison may be carried out manually or with the aid of the local homology algorithm by Smith and Waterman, 1981, Ads App. Math. 2, 482, with the aid of the local homology algorithm by Neddleman and Wunsch, 1970, J. Mol. Biol. 48, 443, with the aid of the similarity search algorithm by Pearson and Lipman, 1988, Proc. Natl Acad. Sci. USA 88, 2444, or with the aid of computer programs using said algorithms (GAP, BESTFIT, FASTA, BLAST P, BLAST N and TFASTA in Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.). In some embodiments, percent identity of two sequences is determined using the BLASTN or BLASTP algorithm, as available on the United States National Center for Biotechnology Information (NCBI) website (e.g., at blast, ncbi.n Im. nih.gov / Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_SPEC=blast2seq&LINK_LOC =align2seq). In some embodiments, the algorithm parameters used for BLASTN algorithm on the NCBI website include: (i) Expect Threshold set to 10; (ii) Word Size set to 28; (iii) Max matches in a query range set to 0; (iv) Match / Mismatch Scores set to 1, -2; (v) Gap Costs set to Linear; and (vi) the filter for low complexity regions being used. In some embodiments, the algorithm parameters used for BLASTP algorithm on the NCBI website include: (i) Expect Threshold set to 10; (ii) Word Size set to 3; (iii) Max matches in a query range set to 0; (iv) Matrix set to BLOSUM62; (v) Gap Costs set to Existence: 11 Extension: 1; and (vi) conditional compositional score matrix adjustment.

[0212] Percentage identity is obtained by determining the number of identical positions at which the sequences to be compared correspond, dividing this number by the number of positions compared (e.g., the number of positions in the reference sequence) and multiplying this result by 100.

[0213] In some embodiments, the degree of similarity or identity is given for a region which is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or about 100% of the entire length of the reference sequence. For example, if the reference nucleic acid sequence consists of 200 nucleotides, the degree of identity is given for at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 nucleotides, in some embodiments continuous nucleotides. In some embodiments, the degree of similarity or identity is given for the entire length of the reference sequence.

[0214] Homologous amino acid sequences exhibit according to the disclosure at least 40%, in particular at least 50%, at least 60%, at least 70%, at least 80%, at least 90% and preferably at least 95%, at least 98 or at least 99% identity of the amino acid residues.

[0215] The amino acid sequence variants described herein may readily be prepared by the skilled person, for example, by recombinant DNA manipulation. The manipulation of DNA sequences for preparing peptides or proteins having substitutions, additions, insertions or deletions, is described in detail in Sambrook et al. (1989), for example. Furthermore, the peptides and amino acid variants described herein may be readily prepared with the aid of known peptide synthesis techniques such as, for example, by solid phase synthesis and similar methods.

[0216] In one embodiment, a fragment or variant of an amino acid sequence (peptide or protein) is preferably a "functional fragment" or "functional variant". The term "functional fragment" or "functional variant" of an amino acid sequence relates to any fragment or variant exhibiting one or more functional properties identical or similar to those of the amino acid sequence from which it is derived, i.e., it is functionally equivalent. With respect to antigens or antigenic sequences, one particular function is one or more immunogenic activities displayed by the amino acid sequence from which the fragment or variant is derived. The term "functional fragment" or "functional variant", as used herein, in particular refers to a variant molecule or sequence that comprises an amino acid sequence that is altered by one or more amino acids compared to the amino acid sequence of the parent molecule or sequence and that is still capable of fulfilling one or more of the functions of the parent molecule or sequence, e.g., inducing an immune response. In one embodiment, the modifications in the amino acid sequence of the parent molecule or sequence do not significantly affect or alter the characteristics of the molecule or sequence. In different embodiments, the function of the functional fragment or functional variant may be reduced but still significantly present, e.g., immunogenicity of the functional variant may be at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the parent molecule or sequence. However, in other embodiments, immunogenicity of the functional fragment or functional variant may be enhanced compared to the parent molecule or sequence.

[0217] An amino acid sequence (peptide, protein or polypeptide) "derived from" a designated amino acid sequence (peptide, protein or polypeptide) refers to the origin of the first amino acid sequence. Preferably, the amino acid sequence which is derived from a particular amino acid sequence has an amino acid sequence that is identical, essentially identical or homologous to that particular sequence or a fragment thereof. Amino acid sequences derived from a particular amino acid sequence may be variants of that particular sequence or a fragment thereof. For example, it will be understood by one of ordinary skill in the art that the antigens suitable for use herein may be altered such that they vary in sequence from the naturally occurring or native sequences from which they were derived, while retaining the desirable activity of the native sequences.

[0218] As used herein, an "instructional material" or "instructions" includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the compositions and methods of the present disclosure. The instructional material of the kit of the present disclosure may, for example, be affixed to a container which contains the compositions of the present disclosure or be shipped together with a container which contains the compositions. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the compositions be used cooperatively by the recipient. "Isolated" means altered or removed from the natural state. For example, a nucleic acid or a peptide naturally present in a living animal is not "isolated", but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is "isolated". An isolated nucleic acid or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell.

[0219] The term "recombinant" in the context of the present disclosure means "made through genetic engineering". Preferably, a "recombinant object" such as a recombinant nucleic acid in the context of the present disclosure is not occurring naturally.

[0220] The term "naturally occurring" as used herein refers to the fact that an object can be found in nature. For example, a peptide or nucleic acid that is present in an organism (including viruses) and can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally occurring.

[0221] "Physiological pH" as used herein refers to a pH of about 7.5.

[0222] The term "genetic modification" or simply "modification" includes the transfection of cells with nucleic acid. The term "transfection" relates to the introduction of nucleic acids, in particular RNA, into a cell. For purposes of the present disclosure, the term "transfection" also includes the introduction of a nucleic acid into a cell or the uptake of a nucleic acid by such cell, wherein the cell may be present in a subject, e.g., a patient. Thus, according to the present disclosure, a cell for transfection of a nucleic acid described herein can be present in vitro or in vivo, e.g. the cell can form part of an organ, a tissue and / or an organism of a patient. According to the present disclosure, transfection can be transient or stable. For some applications of transfection, it is sufficient if the transfected genetic material is only transiently expressed. RNA can be transfected into cells to transiently express its coded protein. Since the nucleic acid introduced in the transfection process is usually not integrated into the nuclear genome, the foreign nucleic acid will be diluted through mitosis or degraded. Cells allowing episomal amplification of nucleic acids greatly reduce the rate of dilution. If it is desired that the transfected nucleic acid actually remains in the genome of the cell and its daughter cells, a stable transfection must occur. Such stable transfection can be achieved by using virus-based systems or transposon-based systems for transfection. Generally, nucleic acid encoding antigen is transiently transfected into cells. RNA can be transfected into cells to transiently express its coded protein.

[0223] The term "seroconversion" includes a >4-fold rise from before vaccination to 1-month post Dose 2.

[0224] Coronavirus

[0225] Coronaviruses are enveloped, positive-sense, single-stranded RNA ((+) ssRNA) viruses. They have the largest genomes (26-32 kb) among known RNA viruses and are phylogenetically divided into four genera (a, (3, y, and 6), with betacoronaviruses further subdivided into four lineages (A, B, C, and D). Coronaviruses infect a wide range of avian and mammalian species, including humans. Some human coronaviruses generally cause mild respiratory diseases, although severity can be greater in infants, the elderly, and the immunocompromised. Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV), belonging to betacoronavirus lineages C and B, respectively, are highly pathogenic. Both viruses emerged into the human population from animal reservoirs within the last 15 years and caused outbreaks with high case-fatality rates. The outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that causes atypical pneumonia (coronavirus disease 2019; COVID-19) has raged in China since mid-December 2019, and has developed to be a public health emergency of international concern. SARS-CoV- 2 (MN908947.3) belongs to betacoronavirus lineage B. It has at least 70% sequence similarity to SARS-CoV.

[0226] In general, coronaviruses have four structural proteins, namely, envelope (E), membrane (M), nucleocapsid (N), and spike (S). The E and M proteins have important functions in the viral assembly, and the N protein is necessary for viral RNA synthesis. The critical glycoprotein S is responsible for virus binding and entry into target cells. The S protein is synthesized as a single- chain inactive precursor that is cleaved by furin-like host proteases in the producing cell into two noncovalently associated subunits, S1 and S2. The S1 subunit contains the receptor- binding domain (RBD), which recognizes the host-cell receptor. The S2 subunit contains the fusion peptide, two heptad repeats, and a transmembrane domain, all of which are required to mediate fusion of the viral and host-cell membranes by undergoing a large conformational rearrangement. The S1 and S2 subunits trimerize to form a large prefusion spike.

[0227] The S precursor protein of SARS-CoV-2 can be proteolytically cleaved into S1 (685 aa) and S2 (588 aa) subunits. The S1 subunit comprises the receptor-binding domain (RBD), which mediates virus entry into sensitive cells through the host angiotensin-converting enzyme 2 (ACE2) receptor. Antigen

[0228] Many embodiments of the present disclosure comprises the use of RNA encoding an amino acid sequence comprising SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or the immunogenic variant thereof. Thus, the RNA encodes a peptide or protein comprising at least an epitope SARS-CoV-2 S protein or an immunogenic variant thereof for inducing an immune response against coronavirus S protein, in particular SARS-CoV-2 S protein in a subject. The amino acid sequence comprising SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or the immunogenic variant thereof (i.e., the antigenic peptide or protein) is also designated herein as "vaccine antigen", "peptide and protein antigen", "antigen molecule" or simply "antigen". The SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or the immunogenic variant thereof is also designated herein as "antigenic peptide or protein" or "antigenic sequence".

[0229] SARS-CoV-2 coronavirus full length spike (S) protein from the first detected SARS-CoV-2 strain (referred to as the Wuhan strain herein) consists of 1273 amino acids and has the amino acid sequence according to SEQ ID NO: 1:

[0230] MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNG TKRFDNPVLPFNDGVYFASTEKSNI IRGWIFGTTLDSKTQSLLIVNNATNWIKVCEFQFCNDPFLGVYYHKNNK SWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEP LVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETK CTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRI SNCVADYSVLYNSASFS TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYN YLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVWLSFELLHAPATVC GPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITP GTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDI PIGAGICASYQ TQTNSPRRARSVASQSI IAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECS NLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNK VTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAM QMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDWNQNAQALNTLVKQLSSNFGAI SS VLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM SFPQSAPHGWFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQI ITTDNTFVSGN CDWIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDI SGINASWNIQKEIDRLNEVAKNLNESLIDL QELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

[0231] ( SEQ ID NO : 1 )

[0232] For purposes of the present disclosure, the above sequence is considered the wildtype or Wuhan SARS-CoV-2 S protein amino acid sequence. Unless otherwise indicated, position numberings in a SARS-CoV-2 S protein given herein are in relation to the amino acid sequence according to SEQ ID NO: 1. One of skill in the art reading the present disclosure can determine the locations of the corresponding positions in SARS-CoV-2 S protein variants.

[0233] The following Table 1 includes additional exemplary S proteins from various coronavirus variants, including the alpha, beta, gamma, delta, and omicron variants (including omicron BA.1, BA.2 and BA.4 / 5). Unless specified otherwise, "Omicron variant", as used herein, refers to any Omicron variant, including e.g., Omicron variants described herein and descendents thereof.

[0234] Amino acid sequences were obtained from the UniProt database, accessible via the World Wide Web at uniprot.org, or the GenBank database, accessible via the World Wide Web at ncbi.nlm.nih.gov, and the UniProt or GenBank database accession numbers of each spike protein sequence are included in the Table 1. These amino acid sequences correspond to the amino acid sequences of native coronavirus spike proteins. In some aspects, the amino acid sequences of native coronavirus spike proteins encoded by RNA constructs described herein may be modified, as described herein, to produce immunogenic polypeptides comprising variant coronavirus spike proteins that are modifications of native coronavirus spike proteins or fragments thereof. For example, in some aspects, the amino acid sequences of native coronavirus spike proteins encoded by RNA constructs described herein are substituted, as described herein, to produce immunogenic polypeptides comprising variant coronavirus spike proteins that are modifications of native coronavirus spike proteins or fragments thereof.

[0235] Like the amino acid sequences of native coronavirus spike proteins, the amino acid sequences of spike proteins (e.g., including the alpha, beta, gamma, delta, and omicron variants (including omicron BA.1, BA.2, BA.4 / 5) of these SARS-CoV-2 variants encoded by RNA constructs described herein may be modified at the corresponding position, as described herein, to produce immunogenic polypeptides comprising variant coronavirus spike proteins that are modifications of the native variant coronavirus spike proteins or fragments thereof. For example, in some aspects, the amino acid sequences of spike proteins of these SARS-CoV- 2 variants encoded by RNA constructs described herein are substituted, as described herein, to produce immunogenic polypeptides comprising variant coronavirus spike proteins that are modifications of variant coronavirus spike proteins or fragments thereof. Additional variants not specifically set forth below are also contemplated. For example, any variant coronavirus spike protein having 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher sequence identity with the native coronavirus spike protein sequence encoded by RNA constructs described herein may be modified at the corresponding position, (e.g., substituted), as described herein, to produce immunogenic polypeptides comprising variant coronavirus spike proteins that are modifications of native coronavirus spike proteins or fragments thereof.

[0236] Table 1

[0237] In some embodiments, a coronavirus spike protein sequence comprises SEQ ID NO: 105, shown below, which is the SARS-CoV-2 (Omicron BA.4 / 5) sequence represented by SEQ ID NO: 104 (see Table 1), but differs by one amino acid at position 403 and comprises a R403S mutation.

[0238] MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAISGTNGTKRFD NPVLPFNDGVYFASTEKSNIIRGWI FGTTLDSKTQSLLIVNNATNWIKVCEFQFCNDPFLDVYYHKNNKSWMES EFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLGRDLPQGFSALEPLVDLP IGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKS FTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCY GVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVGGNYNYRYRL FRKSNLKPFERDI STEP YQAGNKPCNGVAGVNCYFPLQSYGFRPTYGVGHQPYRVWLSFELLHAPATVCGPKKS TNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTS NQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTKS HRRARSVASQSI IAYTMSLGAENSVAYSNNSIAIPTNFTI SVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQ YGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLAD AGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQI PFAMQMAYR FNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQALNTLVKQLSSKFGAI SSVLNDI LSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQS APHGWFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDWI GIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASWNIQKEIDRLNEVAKNLNESLIDLQELGK YEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT ( SEQ ID NO : 105 )

[0239] Coronavirus Spike Protein Modifications

[0240] In specific embodiments, full length spike (S) protein (e.g., the full length S protein of SEQ ID NO: 1) is modified in such a way that the prototypical prefusion conformation is stabilized. Certain mutations that stabilize a prefusion confirmation are known in the art, e.g., as disclosed in WO 2022 / 266010 Al, WO 2021243122 A2 and Hsieh, Ching-Lin, et al. ("Structure- based design of prefusion-stabilized SARS-CoV-2 spikes," Science 369.6510 (2020): 1501- 1505), the contents of each which are incorporated by reference herein in their entirety. In some embodiments, a SARS-CoV-2 S protein may be stabilized by introducing one or more glycine mutations (e.g., one or more glycine mutations in the crown of the helix turn region in the S protein, in the 12 amino acids between the heptad region 1 (HR1) and central helix (CH) or heptad regoin 2 (HR2) regions of the S2 subunit, and / or at one or more of L984, D985, K986, and V987 of (positions relative to SEQ ID NO: 1)). In some embodiments, a Spike protein comprises glycine mutations at each of L984, D985, K986, and V987 (i.e., at positions corresponding to these residues in SEQ ID NO: 1). In some embodiments, a SARS-CoV-2 S protein may be stabilized by introducing one or more proline mutations. In some embodiments, a SARS-CoV-2 S protein comprises a proline substitution at residues 986 and / or 987 of SEQ ID NO: 1. In some embodiments, a SARS-CoV-2 S protein comprises a proline substitution at one or more of residues 817, 892, 899, and 942 of SEQ ID NO: 1. In some embodiments, a SARS-CoV-2 S protein comprises a proline substitution at each of residues 817, 892, 899, and 942 of SEQ ID NO: 1. In some embodiments, a SARS-CoV-2 S protein comprises a proline substitution at each of residues 817, 892, 899, 942, 986, and 987 of SEQ ID NO: 1.

[0241] In some embodiments, a SARS-CoV-2 S protein comprises a proline substitution at residues 985 and / or 987 of SEQ ID NO: 1. In some embodiments, a SARS-CoV-2 S protein comprises a proline substitution at each of residues 817, 892, 899, 942, 985, and 987 of SEQ ID NO: 1.

[0242] In some embodiments, stabilization of the prefusion conformation may be obtained by introducing two consecutive proline substitutions at AS residues 986 and 987 in the full length spike protein. Specifically, spike (S) protein stabilized protein variants are obtained in a way that the amino acid residue at position 986 is exchanged to proline and the amino acid residue at position 987 is also exchanged to proline. In one embodiment, a SARS-CoV-2 S protein variant wherein the prototypical prefusion conformation is stabilized comprises the amino acid sequence shown in SEQ ID NO: 7:

[0243] MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNG TKRFDNPVLPFNDGVYFASTEKSNI IRGWIFGTTLDSKTQSLLIVNNATNWIKVCEFQFCNDPFLGVYYHKNNK SWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEP LVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETK CTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRI SNCVADYSVLYNSASFS TFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYN YLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVWLSFELLHAPATVC GPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITP GTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDI PIGAGICASYQ TQTNSPRRARSVASQSI IAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECS NLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNK VTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAM QMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDWNQNAQALNTLVKQLSSNFGAI SS VLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM SFPQSAPHGWFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQI ITTDNTFVSGN CDWIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDI SGINASWNIQKEIDRLNEVAKNLNESLIDL

[0244] QELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT ( SEQ ID NO : 7 )

[0245] In some embodiments, a Spike protein can be modified in such a way as to block a pre-fusion to post-fusion conformational change (referred to herein as a "pre-post fusion block"). In some embodiments, a pre-post fusion block can be introduced by introducing two cysteine mutations at residues close to one another in the folded protein (e.g., at locations close to one another in a pre-fusion conformation of the Spike protein). Examples of pre-post fusion block mutations include L984C-A989C and I980C-Q992C.

[0246] In some embodiments, a Spike protein can be modified so as to decrease "shedding" (i.e., decrease separation of S1 and S2 subunits). In some embodiments, a Spike protein can be modified to decrease shedding by introducing mutations at the furin cleavage site, such that a furin protease can no longer bind and / or cleave the S protein (e.g., one or more mutations at residues 682-685 of SEQ ID NO: 1). In some embodiments, an S protein can be modified to reduce shedding by introducing mutations at each of residues 682, 683, and 685 (e.g., introducing mutations (i) R682G, R683S, and R685S, or (ii) R682Q, R683Q, and R685Q).

[0247] In some embodiments, an S protein can be modified so as to reduce shedding by introducing cysteine mutations that can form a disulfide bond (e.g., by introducing cysteine mutations at positions that are close to one another in a folded conformation of an S protein, e.g., at residues A570 and N960).

[0248] In some embodiments, one or more modifications may be introduced into a Spike protein so as to stabilize an "up" confirmation (referred to herein as "RBD Up" mutations). Without wishing to be bound by theory, the up confirmation of the SARS-CoV-2 Spike protein is thought to increase exposure of neutralization sensitive residues. Thus, mutations that stabilize the up conformation can produce a vaccine that is more immunogenic.

[0249] The following Table 2 lists various combinations of amino acid modifications that can be introduced into coronavirus spike protein sequences disclosed above and thus polynucleotides (e.g., RNAs) encoding immunogenic polypeptides comprising coronavirus spike proteins that are variants of native coronavirus spike proteins or fragments thereof can be produced. A "+" symbol indicates the inclusion of the specified modification in a particular S protein sequence from a coronvirus strain or variant (e.g., SARS-CoV-2 strains and / or variants as described in Table 1). In some instances, a spike protein sequence may contain any combination of the modifications in the following Table 2. The amino acid positions indicated in Table 2 are numbered relative to SEQ ID. NO: 1 (Wuhan), SEQ ID NO: 69 (Omicron BA.1), SEQ ID NO: 70 (Omicron BA.2), and SEQ ID NO: 104 (Omicron BA.4 / 5). The amino acid positions corresponding to spike protein sequences from other coronavirus variants (e.g., alpha, beta, or delta variant) can determined through an alignment with SEQ ID NO: 1 (see e.g., Table 5).

[0250] Table 2

[0251]

[0252] The following Table 3 lists various combinations of amino acid modifications that can be introduced into coronavirus spike protein sequences disclosed above and thus polynucleotides (e.g., RNAs) encoding immunogenic polypeptides comprising coronavirus spike proteins that are variants of native coronavirus spike proteins or fragments thereof can be produced. Table 3, like Table 2, lists the position of amino acid modifications (with respect to the Wuhan spike protein sequence according to SEQ ID NO: 1), and Table 3 also include the specific amino acid residue that is substituted for the native amino acid residue. A "+" symbol indicates the inclusion of the specified modification in a particular S protein sequence from a coronavirus strain or variant (e.g., SARS-CoV-2 strains and / or variants as described in Table 1). In some instances, a coronavirus spike protein variant encoded by an RNA vaccine may contain any combination of the modifications in Table 2 above, and for example, may include any of the specific substitutions shown in Table 3. The amino acid positions indicated in Table 2 are numbered relative to SEQ ID. NO: 1 (Wuhan), SEQ ID NO: 69 (Omicron BA.1), SEQ ID NO: 70 (Omicron BA.2), and SEQ ID NO: 104 (Omicron BA.4 / 5). The amino acid positions corresponding to spike protein sequences from other coronavirus variants (e.g., alpha, beta, or delta variant) can determined through an alignment with SEQ ID NO: 1 (see e.g., Table 5).

[0253] The following Table 4 lists various combinations of amino acid modifications that can be introduced into coronavirus spike protein sequences disclosed herein (see e.g., Table 1) and thus polynucleotides (e.g., RNAs) encoding immunogenic polypeptides comprising coronavirus spike proteins that are variants of native coronavirus spike proteins or fragments thereof can be produced. A "+" symbol indicates the inclusion of the specified modification in a particular S protein sequence from a coronavirus strain or variant (e.g., SARS-CoV-2 strains and / or variants as described in Table 1). In some instances, a spike protein seqeunce may contain any combination of the modifications in the following Table 4. The amino acid positions indicated in Table 4 are numbered relative to SEQ ID. NO: 69 (SARS-CoV-2 Omicron UFO69279.1 (BA.1, previously B.1.1.529) in Table 1), and the corresponding amino acid positions in other coronavirus spike proteins can be determined through sequence alignments (see e.g., alignment of various coronavirus spike protein sequences in Table 5).

[0254] Table 4

[0255] Non-lnclusive Coronavirus Spike Protein Modification Combinations

[0256]

[0257] In some embodiments, the amino acid corresponding to the amino acid at position 326 in SEQ ID. NO: 69 (SARS-CoV-2 Omicron UFO69279.1 (BA.1, previously B.1.1.529) can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 326 in SEQ ID NO:69 can be substituted with a serine residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a serine residue at 326 may be referred to herein as 326S.

[0258] In some embodiments, the amino acid corresponding to the amino acid at position 364 in SEQ ID. NO: 69 (SARS-CoV-2 Omicron UFO69279.1 (BA.1, previously B.1.1.529) can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 364 in SEQ ID NO:69 can be substituted with a phenylalanine residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a phenylalanine residue at 364 may be referred to herein as 364F. In some embodiments, the amino acid corresponding to the amino acid at position 567 in SEQ ID NO:69 can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 567 in SEQ ID NO:69 can be substituted with a cysteine residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a cysteine residue at 567 may be referred to herein as 567C.

[0259] In some embodiments, the amino acid corresponding to the amino acid at position 611 in SEQ ID NO:69 can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 611 in SEQ ID NO:69 can be substituted with a glycine residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a glycine residue at 611 may be referred to herein as 611G.

[0260] In some embodiments, the amino acid corresponding to the amino acid at position 814 in SEQ ID NO:69 can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 814 in SEQ ID NO:69 can be substituted with a phenylalanine residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a phenylalanine residue at 814 may be referred to herein as 814P.

[0261] In some embodiments, the amino acid corresponding to the amino acid at position 840 in SEQ ID NO:69 can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 840 in SEQ ID NO:69can be substituted with an asparagine residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a asparagine residue at 840 may be referred to herein as 840N.

[0262] In some embodiments, the amino acid corresponding to the amino acid at position 851 in SEQ ID NO:69can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 851 in SEQ ID NO:69can be substituted with a phenylalanine residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a phenylalanine residue at 851 may be referred to herein as 851F.

[0263] In some embodiments, the amino acid corresponding to the amino acid at position 889 in SEQ ID NO:69can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 889 in SEQ ID NO:69 can be substituted with a proline residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a proline residue at 889 may be referred to herein as 889P.

[0264] In some embodiments, the amino acid corresponding to the amino acid at position 896 in SEQ ID NO:69can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 896 in SEQ ID NO:69 can be substituted with a proline residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a proline residue at 896 may be referred to herein as 896P.

[0265] In some embodiments, the amino acid corresponding to the amino acid at position 939 in SEQ ID NO:69can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 939 in SEQ ID NO:69can be substituted with a proline residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a proline residue at 939 may be referred to herein as 939P.

[0266] In some embodiments, the amino acid corresponding to the amino acid at position 957 in SEQ ID NO:69 can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 957 in SEQ ID NO:69can be substituted with a cysteine residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a cysteine residue at 957 may be referred to herein as 957C.

[0267] In some embodiments, the amino acid corresponding to the amino acid at position 977 in SEQ ID NO:69can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 977 in SEQ ID NO:69can be substituted with a cysteine residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a cysteine residue at 977 may be referred to herein as 977C.

[0268] In some embodiments, the amino acid corresponding to the amino acid at position 981 in SEQ ID NO:69can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 981 in SEQ ID NO:69can be substituted with a cysteine residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a cysteine residue at 981 may be referred to herein as 981C.

[0269] In some embodiments, the amino acid corresponding to the amino acid at position 982 in SEQ ID NO:69can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 982 in SEQ ID NO:69can be substituted with a proline residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a proline residue at 982 may be referred to herein as 982P.

[0270] In some embodiments, the amino acid corresponding to the amino acid at position 983 in SEQ ID NO:69can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 983 in SEQ ID NO:69can be substituted with a proline residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a proline residue at 983 may be referred to herein as 983P.

[0271] In some embodiments, the amino acid corresponding to the amino acid at position 984 in SEQ ID NO:69can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 984 in SEQ ID NO:69can be substituted with a proline residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a proline residue at 983 may be referred to herein as 984P.

[0272] In some embodiments, the amino acid corresponding to the amino acid at position 986 in SEQ

[0273] ID NO:69can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 986 in SEQ ID NO:69can be substituted with a cysteine residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a cysteine residue at 986 may be referred to herein as 986C.

[0274] In some embodiments, the amino acid corresponding to the amino acid at position 989 in SEQ ID NO:69can be substituted to produce a variant coronavirus spike protein encoded by RNA as described herein. In some embodiments, the amino acid corresponding to the amino acid at position 989 in SEQ ID NO:69can be substituted with a cysteine residue to produce a variant coronavirus spike protein encoded by RNA as described herein. A substitution with a cysteine residue at 989 may be referred to herein as 989C.

[0275] In some embodiments, a variant spike protein encoded by RNA described herein has, at least, or has at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, and / or 18 of the following modifications at positions 326, 364, 567, 611, 814, 840, 851, 889, 896, 939, 957, 977, 981, 982, 983, 984, 986, 989 as set forth in SARS-CoV-2 Omicron (BA.1, previously B.l.1.529) spike protein, UniProt Accession Number UFO69279.1, or the corresponding amino acid in the spike protein of another coronavirus, wherein in some embodiments the modification at the position or corresponding position 326 is a serine, 364 is a phenylalanine, 567 is a cysteine, 611 is a glycine, 814 is a proline, 840 is a asparagine, 851 is a phenylalanine, 889 is a proline, 896 is a proline, 939 is a proline, 957 is a cysteine, 977 is a cysteine, 981 is a cysteine, 982 is a proline, 983 is a proline, 984 is a proline, 986 is a cysteine, and 989 is a cysteine and wherein in further embodiments the variant spike protein has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to a SARS-CoV-2 Omicron (BA.1, previously B.l.1.529) spike protein, UniProt Accession Number UFO69279.1. In some instances, the modifications described herein may be applied alone or in combination with any one or more additional modifications described herein to produce an RNA (e.g., as described herein) encoding an immunogenic polypeptide comprising a variant coronavirus spike protein that is a variant of a native coronavirus spike protein or fragment thereof. In some embodiments, these modifications may (a) increase adoption by RBDs of the variant coronavirus spike proteins of the RBD-up conformation to expose more neutralization- sensitive epitopes on the spike protein, (b) decrease adoption by RBDs of the variant coronavirus spike proteins of the RBD-down conformation, (c) increase expression of the variant coronavirus spike protein compared to the native coronavirus spike protein, (d) increase adoption of a prefusion conformation, (e) decrease shedding of a S s1ubunit of the variant coronavirus spike protein, and / or (f) improve localization of the variant coronavirus spike protein to a host cell membrane.

[0276] Mutations described herein and e.g., in Tables 2A, 2B, and 2C may be introduced into S protein sequence of other coronavirus strains or variant sequences, or immunogenic fragments thereof, and the corresponding position may be determined through a sequence alignment with SEQ ID NO: 69 (see e.g., Table 5).

[0277] In some embodiments, a variant spike protein encoded by RNA described herein, has at least, or has at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, and / or 18 of the following modifications at positions 326, 364, 567, 611, 814, 840, 851, 889, 896, 939, 957, 977, 981, 982, 983, 984, 986, 989 as set forth in SARS-CoV-2 Omicron (BA.1, previously B.l.1.529) spike protein, UniProt Accession Number UFO69279.1, or the corresponding amino acid in the spike protein of another coronavirus, wherein in some embodiments the modification at the position or corresponding position 326 is to any amino acid except phenylalanine, 364 is any amino acid except valine, 567 is any amino acid except alanine, 611 is any amino acid except glycine, 814 is any amino acid except phenylalanine, 840 is any amino acid except aspartic acid, 851 is any amino acid except lysine, 889 is any amino acid except alanine, 896 is any amino acid except alanine, 939 is any amino acid except alanine, 957 is any amino acid except asparagine, 977 is any amino acid except isoleucine, 981 is any amino acid except leucine, 982 is any amino acid except aspartic acid, 983 is any amino acid except lysine, 984 is any amino acid except valine, 986 is any amino acid except alanine, and 989 is any amino acid except glutamine, and wherein in further embodiments the variant spike protein has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to a SARS-CoV-2 Omicron (BA.1, previously B.l.1.529) spike protein, UniProt Accession Number UFO69279.1. In some instances, the modifications described herein may be applied alone or in combination with any one or more additional modifications described herein to produce an RNA encoding isolated immunogenic polypeptide comprising a variant coronavirus spike protein that is a variant of a native coronavirus spike protein or fragment thereof. In some embodiments, these modifications may (a) increase adoption by RBDs of the variant coronavirus spike proteins of the RBD-up conformation to expose more neutralization- sensitive epitopes on the spike protein, (b) decrease adoption by RBDs of the variant coronavirus spike proteins of the RBD-down conformation, (c) increase expression of the variant coronavirus spike protein compared to the native coronavirus spike protein, (d) increase adoption of a prefusion conformation, (e) decrease shedding of a S s1ubunit of the variant coronavirus spike protein, and / or (f) improve localization of the variant coronavirus spike protein to a host cell membrane.

[0278] The amino acids in each human coronavirus spike protein sequence and the corresponding position of that amino acid with respect to SEQ ID NO:1 can be determined based an alignment of the protein sequences. Below in Table 5 is an alignment of human coronavirus spike protein sequences (e.g., the spike protein sequences of Table 1). The highlighted positions in the below alignment correspond to the location of the amino acids to be modified identified in the Table 2 above.

[0279]

[0280]

[0281]

[0282]

[0283]

[0284]

[0285] Coronavirus Variants

[0286] Those skilled in the art are aware of various spike variants, and / or resources that document them. For example, the following strains, their SARS-CoV-2 S protein amino acid sequences and, in particular, modifications thereof compared to wildtype SARS-CoV-2 S protein amino acid sequence, e.g., as compared to SEQ ID NO: 1, are useful herein.

[0287] B.l.1.7 ("Variant of Concern 202012 / 01" (VOC-202012 / 01)

[0288] B.l.1.7 is a variant of SARS-CoV-2 which was first detected in October 2020 during the COVID- 19 pandemic in the United Kingdom from a sample taken the previous month, and it quickly began to spread by mid-December. It is correlated with a significant increase in the rate of COVID-19 infection in United Kingdom; this increase is thought to be at least partly because of change N501Y inside the spike glycoprotein's receptor-binding domain, which is needed for binding to ACE2 in human cells. The B.l.1.7 variant is defined by 23 mutations: 13 non- synonymous mutations, 4 deletions, and 6 synonymous mutations (i.e., there are 17 mutations that change proteins and six that do not). The spike protein changes in B.l.1.7 include deletion 69-70, deletion 144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H.

[0289] B.1.351 (501.V2)

[0290] B.1.351 lineage and colloquially known as South African COVID-19 variant, is a variant of SARS- CoV-2. Preliminary results indicate that this variant may have an increased transmissibility. The B.1.351 variant is defined by multiple spike protein changes including: L18F, D80A, D215G, deletion 242-244, R246I, K417N, E484K, N501Y, D614G and A701V. There are three mutations of particular interest in the spike region of the B.1.351 genome: K417N, E484K, N501Y.

[0291] B.1.1.298 (Cluster 5)

[0292] B.l.1.298 was discovered in North Jutland, Denmark, and is believed to have been spread from minks to humans via mink farms. Several different mutations in the spike protein of the virus have been confirmed. The specific mutations include deletion 69-70, Y453F, D614G, 1692V, M1229I, and optionally S1147L.

[0293] P.l (B.l.1.248)

[0294] Lineage B.l.1.248, known as the Brazil(ian) variant, is one of the variants of SARS-CoV-2 which has been named P.l lineage. P.l has a number of S-protein modifications [L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F] and is similar in certain key RBD positions (K417, E484, N501) to variant B.1.351 from South Africa. B.1.427 / B.1.429 (CAL.20C)

[0295] Lineage B.1.427 / B.1.429, also known as CAL.20C, is defined by the following modifications in the S-protein: S13I, W152C, L452R, and D614G of which the L452R modification is of particular concern. CDC has listed B.1.427 / B.1.429 as "variant of concern".

[0296] B.1.525

[0297] B.1.525 carries the same E484K modification as found in the P.l, and B.1.351 variants, and also carries the same AH69 / AV70 deletion as found in B.1.1.7, and B.1.1.298. It also carries the modifications D614G, Q677H and F888L.

[0298] B.1.526

[0299] B.1.526 was detected as an emerging lineage of viral isolates in the New York region that shares mutations with previously reported variants. The most common sets of spike mutations in this lineage are L5F, T95I, D253G, E484K, D614G, and A701V.

[0300] The following table shows an overview of circulating SARS-CoV-2 strains which are VOI / VOC.

[0301] Table 6: Overview of circulating SARS-CoV-2 strains which are VOI / VOC

[0302] Lineage Amino acid substitution

[0303] B.l.1.529

[0304] B.1.529 ("Omicron") was first detected in South Africa in November 2021. Omicron has been found to multiply around 70 times faster than Delta variants, and quickly became the dominant strain of SARS-CoV-2 worldwide. Since its initial detection, a number of sublineages have arisen. Listed in the below Table 3A are current Omicron variants of concern, along with certain characteristic mutations associated with the S protein of each (mutation positions shown relative to SEQ ID NO: 1). In some embodiments, BA.4 and BA.5 variants have the same S protein amino acid sequence, in which case the term "BA.4 / 5" may be used to refer to an amino acid sequence of an S protein that can be found in either of BA.4 or BA.5. Similarily, in some embodiments, BA.4.6 and BF.7 variants have the same protein amino acid sequence, in which case the term "BA.4.6 / BF.7" can be used to refer to an amino acid sequence of an S protein present in either of BA.4.6 or BF.7.

[0305] Table 3A: Omicron Variants of Concern and Characteristic mutations

[0306] In addition to the above Omicron variants, further variants of BA.5 have been observed (such variants including, e.g., BF.14) comprising one of more of the following mutations in the S protein (positions shown relative to SEQ ID NO: 1): E340X (e.g., E340K), R346X (e.g., R346T, R346I, or R346S), K444X (e.g., K444N or K444T), V445X, 5 N450D, and S:N460X (e.g., N460K). In some embodiments, RNA described herein comprises a nucleotide sequence encoding a SARS-CoV-2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 5 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) characteristic of an Omicron variant (e.g., one or more mutations of an Omicron variant listed in Table 3A) and one or more mutations that stabilize the S protein in a pre-fusion confirmation. In some embodiments, an RNA comprises a nucleotide sequence encoding a SARS-CoV-2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 6, 7 , 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) listed in Table 3A. In some such embodiments, one or more mutations may come from two or more variants as listed in Table 3A. In some embodiments, an RNA comprises a nucleotide sequence encoding a SARS-CoV-2 S protein comprising each of the mutations identified in Table 3A as being characteristic of a certain Omicron variant (e.g., in some embodiments, an RNA comprises a nucleotide sequence encoding a SARS-CoV-2 S protein comprising each of the mutations listed in Table 3A as being characteristic of an Omicron BA.1, BA.2, BA.2.12.1, BA.4 / 5, BA.2.75, BA.2.75.1, BA.4.6, BQ.1.1, XBB, XBB.l, XBB.2, or XBB.1.3 variant).

[0307] In some embodiments, an RNA disclosed herein comprises a nucleotide sequence that encodes an immunogenic fragment of the SARS-Cov-2 S protein (e.g., the RBD) and which comprises one or more mutations that are characteristic of a SARS-CoV-2 variant (e.g., an Omicron variant described herein). For example, in some embodiments, an RNA comprises a nucleotide sequence encoding the RBD of an S protein of a SARS-CoV-2 variant (e.g., a region of the S protein corresponding to amino acids 327 to 528 of SEQ ID NO: 1, and comprising one or more mutations characteristic of a variant of concern that lie within this region).

[0308] In some embodiments, an RNA encodes a SARS-CoV-2 S protein comprising a subset of the mutations listed in Table 3A. In some embodiments, an RNA encodes a SARS-CoV-2 S protein comprising the mutations listed in Table 3A that are most prevalent in a certain variant (e.g., mutations that have been detected in at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of sequences collected to date for a given variant sequenced). Mutation prevalence can be determined, e.g., based on published sequences (e.g., sequences that are collected and made available to the public by GISAID).

[0309] In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations that are characteristic of a BA.4 / 5 variant. In some embodiments, the one or more mutations characteristic of a BA.4 / 5 variant include T19I, A24-26, A27S, AO24-26, A27S, A69 / 70, G142D, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, and N969K. In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations that are characteristic of a BA.4 / 5 variant and excludes R408S. In some embodiments, RNA described herein encodes a SARS- CoV-2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) that are characteristic of a BA.4 / 5 variant and excludes R408S.

[0310] In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more (including, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) mutations characteristic of a BA.2.75 variant. In some embodiments, the one or more mutations characteristic of a BA.2.75 variant include T19I, A24-26, A27S, G142D, K147E, W152R, F157L, 1210V, V213G, G257S, G339H, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, G446S, N460K, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, and N969K. In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations that are characteristic of a BA.4 / 5 variant and excludes R408S. In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15 14, 15, 16, 17, 18, 19, 20, or more) that are characteristic of a BA.4 / BA.5 variant, and which excludes R408S and N354D. In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more (including, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) mutations characteristic of a BA.2.75 variant. In some embodiments, the one or more mutations characteristic of a BA.2.75 variant include T19I, A24-26, A27S, G142D, K147E, W152R, F157L, 1210V, V213G, G257S, G339H, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, G446S, N460K, S477N, T478K, E484A, Q498R, N501Y, Y505H D614G, H655Y, N679K, P681H, N764K, Q954H, and N969K. In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 25 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) that are characteristic of a BA.2.75 variant, and which excludes N354D. In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) that are characteristic of a BA.2.75 variant, and which excludes D796Y. In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 6, 7 , 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) that are characteristic of a BA.2.75 variant, and which excludes D796Y and N354D.

[0311] In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations characteristic of a BA.2.75.2 variant. In some embodiments, the one or more mutations characteristic of a BA.2.75.2 variant include T19I, A24-26, A27S, G142D, K147E, W152R, F157L, 1210V, V213G, G257S, G339H, R346T, N354D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, G446S, N460K, S477N, T478K, E484A, F486S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K, and D1199N. In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 30 14, 15, 16, 17, 18, 19, 20, or more) that are characteristic of a BA.2.75.2 variant, and which excludes R346T.

[0312] In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations characteristic of a BA.4.6 or BF.7 variant. In some embodiments, the one or more mutations characteristic of a BA.4.6 or BF.7 variant include T19I, A24-26, A27S, A69 / 70, G142D, V213G, G339D, R346T, S371F, S373P, S375F, T376A, D405N, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, and N969K. In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) that are characteristic of a BA.4.6 or BF.7 variant, and which exclude R408S. In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) that are characteristic of a BA.4.6 or BF.7 variant, and which exclude N658S. In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 25 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) that are characteristic of a BA.4.6 or BF.7 variant, and which exclude N658S and R408S.

[0313] In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations characteristic of an Omicron XBB variant. In some embodiments, the one or more mutations characteristic of an Omicron XBB variant include T19I, A24-26, A27S, V83A, G142D, A144, H146Q, Q183E, V213E, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486S, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, and N969K.

[0314] In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations characteristic of an Omicron XBB.l variant. In some embodiments, the one or more mutations characteristic of an Omicron XBB.l variant include G252V. In some embodiments, the one or more mutations characteristic of an Omicron XBB.l variant include T19I, A24-26, A27S, V83A, G142D, A144, H146Q, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486S, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, and N969K. In some embodiments, RNA described herein encodes a SARS- CoV-2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) that are characteristic of an Omicron XBB.l variant and which exclude Q493R. In some embodiments, RNA described herein encodes a SARS-CoV- 2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15 13, 14, 15, 16, 17, 18, 19, 20, or more) that are characteristic of an Omicron XBB variant and which exclude Q493R and G252V.

[0315] In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations characteristic of an Omicron XBB.2 variant. In some embodiments, the one or more mutations characteristic of an Omicron XBB.2 variant include D253G. In some embodiments, the one or more mutations characteristic of an Omicron XBB.2 variant include T19I, A24-26, A27S, V83A, G142D, A144, H146Q, Q183E, V213E, D253G, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486S, F490S, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, and N969K.

[0316] In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations characteristic of an Omicron XBB.1.3 variant. In some embodiments, the one or more mutations characteristic of an Omicron XBB.l.3 variant include G252V and A484T. In some embodiments, the one or more mutations characteristic of an Omicron XBB.1.3 variant include T19I, A24-26, A27S, V83A, G142D, A144, H146Q, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, A484T, F486S, F490S, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, and N969K.

[0317] In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations that are characteristic of a BQ.1.1 variant. In some embodiments, the one or more mutations characteristic of a BQ.1.1 variant include T19I, A24-26, A27S, A69 / 70, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, N463K, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, and N969K. In some embodiments, RNA described herein encodes a SARS-CoV-2 S protein comprising one or more mutations (including, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) that are characteristic of a BQ.1.1 variant.

[0318] In one embodiment, a vaccine antigen described herein comprises, consists essentially of or consists of a spike protein (S) of SARS-CoV-2, a variant thereof, or a fragment thereof and comprises one or more of mutations characteristic of a SARS-CoV-2 variant (e.g., one or more of mutations associated with an Omicron variant that are listed in Table 3A).

[0319] In one embodiment, a vaccine antigen comprises (a) the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: l or 7, an immunogenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to an immunogenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, and (b) one of more mutations associated with a SARS- CoV-2 variant of concern (e.g., one or more mutations listed in Table 3A). In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7 and comprises one or more associated with a SARS-CoV-2 variant of concern (e.g., one or more mutations listed in Table 3A).

[0320] In one embodiment, a vaccine antigen comprises (a) the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 80, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 80, an immunogenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 80, or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 80, and (b) one of more of the mutations listed in Table 3A. In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 80 and comprises one or more mutations associated with a SARS-CoV-2 variant of concern (e.g., one or more mutations listed in Table 3A).

[0321] In one embodiment, RNA encoding a vaccine antigen (a) comprises (i) the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9, a fragment of the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to a fragment of the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9 and / or (ii) a nucleotide sequence encoding an amino acid sequence comprising the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, an immunogenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to an immongenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, and (b) comprises a nucleotide sequence encoding a SARS-CoV-2 S protein comprising one or more mutations associated with a SARS-CoV-2 variant of concern (e.g., one or more mutations listed in Table 3A)). In one embodiment, RNA encoding a vaccine antigen (a) (i) comprises the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, and (b) comprises one or more mutations characteristics of a SARS- CoV-2 variant of concern (e.g., one or more mutations listed in Table 3A).

[0322] In one embodiment, RNA encoding a vaccine antigen comprises (a) (i) the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 81, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 81, a fragment of the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 81, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to a fragment of the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 81 and / or (ii) a nucleotide sequence encoding encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 80, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 80, an immunogenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 80, or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to an immongenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 80, and (b) comprises one or more mutations associated with a SARS-CoV-2 variant of concern (e.g., one or more mutations listed in Table 3A)). In one embodiment, RNA encoding a vaccine antigen (a) (i) comprises the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 81; and / or (ii) comprises a nucleotide sequence that encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 80 or 7, and (b) comprises one or more mutations characteristics of a SARS-CoV-2 variant of concern (e.g., one or more mutations listed in Table 3A).

[0323] In one embodiment, a vaccine antigen comprises, consists essentially of or consists of SARS- CoV-2 spike S f1ragment (SI) (the s Su1bunit of a spike protein (S) of SARS-CoV-2), a variant thereof, or a fragment thereof, and comprises one or more mutations of a SARS-CoV-2 variant described herein.

[0324] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, an immunogenic fragment of the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to an immunogenic fragment of the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1 and comprises one or more mutations characteristic of a SARS-CoV-2 variant (e.g., one or more mutations listed in Table 3A). In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1 and comprises one or more mutations characteristic of a SARS-CoV-2 variant (e.g., one or more mutations listed in Table 3A).

[0325] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 80, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, an immunogenic fragment of the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to an immunogenic fragment of the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 80 and comprises one or more mutations characteristic of a SARS-CoV-2 variant (e.g., one or more mutations listed in Table 3A). In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 80 and comprises one or more mutations characteristic of a SARS-CoV-2 variant (e.g., one or more mutations listed in Table 3A).

[0326] Vaccine Antigens and Combinations Thereof

[0327] In one embodiment, the vaccine antigen described herein comprises, consists essentially of or consists of a spike protein (S) of SARS-CoV-2, a variant thereof, or a fragment thereof.

[0328] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7. In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7.

[0329] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9, or a fragment of the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7.

[0330] In one embodiment, the vaccine antigen comprises, consists essentially of or consists of SARS- CoV-2 spike S f1ragment (SI) (the S s1ubunit of a spike protein (S) of SARS-CoV-2), a variant thereof, or a fragment thereof.

[0331] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1. In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1.

[0332] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8 or 9, or a fragment of the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8 or 9, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1.

[0333] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1. In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1.

[0334] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8 or 9, or a fragment of the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8 or 9, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1.

[0335] In one embodiment, the vaccine antigen comprises, consists essentially of or consists of the receptor binding domain (RBD) of the su Sb1unit of a spike protein (S) of SARS-CoV-2, a variant thereof, or a fragment thereof. The amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, a variant thereof, or a fragment thereof is also referred to herein as "RBD" or "RBD domain".

[0336] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1. In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1.

[0337] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8 or 9, or a fragment of the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8 or 9, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1.

[0338] According to certain embodiments, a signal peptide is fused, either directly or through a linker, to a SARS-CoV-2 S protein, a variant thereof, or a fragment thereof, i.e., the antigenic peptide or protein. Accordingly, in one embodiment, a signal peptide is fused to the above described amino acid sequences derived from SARS-CoV-2 S protein or immunogenic fragments thereof (antigenic peptides or proteins) comprised by the vaccine antigens described above.

[0339] Such signal peptides are sequences, which typically exhibit a length of about 15 to 30 amino acids and are preferably located at the N-terminus of the antigenic peptide or protein, without being limited thereto. Signal peptides as defined herein preferably allow the transport of the antigenic peptide or protein as encoded by the RNA into a defined cellular compartment, preferably the cell surface, the endoplasmic reticulum (ER) or the endosomal-lysosomal compartment. In one embodiment, the signal peptide sequence as defined herein includes, without being limited thereto, the signal peptide sequence of SARS-CoV-2 S protein, in particular a sequence comprising the amino acid sequence of amino acids 1 to 16 or 1 to 19 of SEQ ID NO: 1 or a functional variant thereof.

[0340] In one embodiment, a signal sequence comprises the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1, or a functional fragment of the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1. In one embodiment, a signal sequence comprises the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1.

[0341] In one embodiment, RNA encoding a signal sequence (i) comprises the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8 or 9, or a fragment of the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8 or 9, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1, or a functional fragment of the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1. In one embodiment, RNA encoding a signal sequence (i) comprises the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1.

[0342] In one embodiment, a signal sequence comprises the amino acid sequence of amino acids 1 to 19 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 19 of SEQ ID NO: 1, or a functional fragment of the amino acid sequence of amino acids 1 to 19 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 19 of SEQ ID NO: 1. In one embodiment, a signal sequence comprises the amino acid sequence of amino acids 1 to 19 of SEQ ID NO: 1.

[0343] In one embodiment, RNA encoding a signal sequence (i) comprises the nucleotide sequence of nucleotides 1 to 57 of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 57 of SEQ ID NO: 2, 8 or 9, or a fragment of the nucleotide sequence of nucleotides 1 to 57 of SEQ ID NO: 2, 8 or 9, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 57 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 19 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 19 of SEQ ID NO: 1, or a functional fragment of the amino acid sequence of amino acids 1 to 19 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 19 of SEQ ID NO: 1. In one embodiment, RNA encoding a signal sequence (i) comprises the nucleotide sequence of nucleotides 1 to 57 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 19 of SEQ ID NO: 1. In some embodiments, an RNA comprises a sequence encoding a signal peptide. In some embodiments, a signal peptide sequence as defined herein includes, without being limited thereto, the signal peptide sequence of an immunoglobulin, e.g., the signal peptide sequence of an immunoglobulin heavy chain variable region, wherein the immunoglobulin may be human immunoglobulin. In particular, in some embodiments, the signal peptide sequence as defined herein can include a sequence comprising the amino acid sequence of amino acids 1 to 22 of SEQ ID NO: 31 or a functional variant thereof.

[0344] In some embodiments, a signal peptide sequence is functional in mammalian cells. In some embodiments, a utilized signal sequence is "intrinsic" in that it is, in nature, associated with (e.g., linked to) the encoded polypeptide. In some embodiments, a utilized signal sequence is heterologous to an encoded polypeptide, e.g., is not naturally part of a polypeptide (e.g., protein) whose sequences are included in the encoded polypeptide. In some embodiments, signal peptides are sequences, which are typically characterized by a length of about 15 to 30 amino acids. In many embodiments, signal peptides are positioned at the N-terminus of an encoded polypeptide as described herein, without being limited thereto. In some embodiments, signal peptides preferably allow the transport of the polypeptide encoded by RNAs of the present disclosure with which they are associated into a defined cellular compartment, preferably the cell surface, the endoplasmic reticulum (ER) or the endosomal- lysosomal compartment. In some embodiments, a signal sequence is selected from an S1S2 signal peptide (aa 1-16 or aa 1-19), an immunoglobulin secretory signal peptide (aa 1-22), an HSV-1 gD signal peptide (MGGAAARLGAVILFVVIVGLHGVRSKY), an HSV-2 gD signal peptide (MGRLTSGVGTAALLVVAVGLRVVCA), a human SPARC signal peptide, a human insulin isoform 1 signal peptide, a human albumin signal peptide, etc. Those skilled in the art will be aware of other secretory signal peptides such as, for example, as disclosed in W02017 / 0810822220 (e.g., SEQ ID NOs: 1-1115 and 1728, or fragments variants thereof) and WQ2019008001. In some embodiments, an RNA sequence encodes an epitope that may comprise or otherwise be linked to a signal sequence (e.g., secretory sequence), such as those listed in Table A, or at least a sequence having 1, 2, 3, 4, or 5 amino acid differences relative thereto. In some embodiments, a signal sequence such as MFVFLVLLPLVSSQCVNLT, or a sequence having at least 1, 2, 3, 4, or at the most 5 amino acid differences relative thereto is utilized. In some embodiments, a sequence such as MFVFLVLLPLVSSQCVNLT, or a sequence having 1, 2, 3, 4, or at most 5 amino acid differences relative thereto, is utilized. In some embodiments, a signal sequence is selected from those included in the Table A below and / or those encoded by the sequences in Table B below.

[0345] Table A: Exemplary signal sequences

[0346] Table B: Exemplary nucleotide sequences encoding signal sequences In one embodiment, a signal sequence comprises the amino acid sequence of amino acids 1 to 22 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 22 of SEQ ID NO: 31, or a functional fragment of the amino acid sequence of amino acids 1 to 22 of SEQ ID NO: 31, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 22 of SEQ ID NO: 31. In one embodiment, a signal sequence comprises the amino acid sequence of amino acids 1 to 22 of SEQ ID NO: 31.

[0347] In one embodiment, RNA encoding a signal sequence (i) comprises the nucleotide sequence of nucleotides 54 to 119 of SEQ ID NO: 32, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 119 of SEQ ID NO: 32, or a fragment of the nucleotide sequence of nucleotides 54 to 119 of SEQ ID NO: 32, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 119 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 22 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 22 of SEQ ID NO: 31, or a functional fragment of the amino acid sequence of amino acids 1 to 22 of SEQ ID NO: 31, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 22 of SEQ ID NO: 31. In one embodiment, RNA encoding a signal sequence (i) comprises the nucleotide sequence of nucleotides 54 to 119 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 22 of SEQ ID NO: 31.

[0348] Such signal peptides are preferably used in order to promote secretion of the encoded antigenic peptide or protein. More preferably, a signal peptide as defined herein is fused to an encoded antigenic peptide or protein as defined herein.

[0349] Accordingly, in particularly preferred embodiments, the RNA described herein comprises at least one coding region encoding an antigenic peptide or protein and a signal peptide, said signal peptide preferably being fused to the antigenic peptide or protein, more preferably to the N-terminus of the antigenic peptide or protein as described herein.

[0350] In one embodiment, a vaccine antigen comprises the amino acid sequence of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 1 or 7, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 1 or 7, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 1 or 7. In one embodiment, a vaccine antigen comprises the amino acid sequence of SEQ ID NO: 1 or 7. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 2, 8 or 9, or a fragment of the nucleotide sequence of SEQ ID NO: 2, 8 or 9, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 1 or 7, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 1 or 7, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 1 or 7. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 1 or 7.

[0351] In one embodiment, a vaccine antigen comprises the amino acid sequence of SEQ ID NO: 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 7, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 7, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 7. In one embodiment, a vaccine antigen comprises the amino acid sequence of SEQ ID NO: 7.

[0352] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 15, 16, 19, 20, 24, or 25, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 15, 16, 19, 20, 24, or 25, or a fragment of the nucleotide sequence of SEQ ID NO: 15, 16, 19, 20, 24, or 25, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 15, 16, 19, 20, 24, or 25; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 7, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 7, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 7. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 15, 16, 19, 20, 24, or 25; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 7.

[0353] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 683 of SEQ ID NO:

[0354] 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1. In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1.

[0355] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 1 to 2049 of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 2049 of SEQ ID NO: 2, 8 or 9, or a fragment of the nucleotide sequence of nucleotides 1 to 2049 of SEQ ID NO: 2, 8 or 9, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 2049 of SEQ ID NO:

[0356] 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 1 to 2049 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1.

[0357] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1. In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1.

[0358] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 1 to 2055 of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 2055 of SEQ ID NO: 2, 8 or 9, or a fragment of the nucleotide sequence of nucleotides 1 to 2055 of SEQ ID NO: 2, 8 or 9, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 2055 of SEQ ID NO:

[0359] 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 1 to 2055 of SEQ ID NO: 2, 8 or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1.

[0360] In one embodiment, a vaccine antigen comprises the amino acid sequence of SEQ ID NO: 3, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 3, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 3, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 3. In one embodiment, a vaccine antigen comprises the amino acid sequence of SEQ ID NO: 3.

[0361] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 4, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 4, or a fragment of the nucleotide sequence of SEQ ID NO: 4, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 4; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 3, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 3, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 3, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 3. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 4; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 3.

[0362] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29. In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29.

[0363] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 716 of SEQ ID NO: 30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 716 of SEQ ID NO: 30, or a fragment of the nucleotide sequence of nucleotides 54 to 716 of SEQ ID NO: 30, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 716 of SEQ ID NO: 30; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 716 of SEQ ID NO: 30; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29.

[0364] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31. In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31.

[0365] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 725 of SEQ ID NO: 32, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 725 of SEQ ID NO: 32, or a fragment of the nucleotide sequence of nucleotides 54 to 725 of SEQ ID NO: 32, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 725 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 725 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31.

[0366] Multimerization Domains

[0367] In some embodiments, an RNA utilized as described herein comprises a sequence that encodes a multimerization element (e.g., a heterologous multimerization element). In some embodiments, a heterologous multimerization element comprises a dimerization, trimerization or tetramerization element. In some embodiments, a multimerization element is one described in W02017 / 081082 (e.g., SEQ ID NOs: 1116-1167, or fragments or variants thereof). Exemplary trimerization and tetramerization elements include, but are not limited to, engineered leucine zippers, fibritin foldon domain from enterobacteria phage T4, GCN4pll, GCN4-pll, and p53. In some embodiments, a provided encoded polypeptide(s) is able to form a trimeric complex. For example, a utilized encoded polypeptide(s) may comprise a domain allowing formation of a multimeric complex, such as for example a trimeric complex of an amino acid sequence comprising an encoded polypeptide(s) as described herein. In some embodiments, a domain allowing formation of a multimeric complex comprises a trimerization domain, for example, a trimerization domain as described herein. In some embodiments, an encoded polypeptide(s) can be modified by addition of a T4-fi briti n- derived "foldon" trimerization domain, for example, to increase its immunogenicity.

[0368] According to certain embodiments, a trimerization domain is fused, either directly or through a linker, e.g., a glycine / serine linker, to a SARS-CoV-2 S protein, a variant thereof, or a fragment thereof, i.e., the antigenic peptide or protein. Accordingly, in one embodiment, a trimerization domain is fused to the above described amino acid sequences derived from SARS-CoV-2 S protein or immunogenic fragments thereof (antigenic peptides or proteins) comprised by the vaccine antigens described above (which may optionally be fused to a signal peptide as described above).

[0369] Such trimerization domains are preferably located at the C-terminus of the antigenic peptide or protein, without being limited thereto. Trimerization domains as defined herein preferably allow the trimerization of the antigenic peptide or protein as encoded by the RNA. Examples of trimerization domains as defined herein include, without being limited thereto, foldon, the natural trimerization domain of T4 fibritin. The C-terminal domain of T4 fibritin (foldon) is obligatory for the formation of the fibritin trimer structure and can be used as an artificial trimerization domain. In one embodiment, the trimerization domain as defined herein includes, without being limited thereto, a sequence comprising the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10 or a functional variant thereof. In one embodiment, the trimerization domain as defined herein includes, without being limited thereto, a sequence comprising the amino acid sequence of SEQ ID NO: 10 or a functional variant thereof. In one embodiment, a trimerization domain comprises the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10, or a functional fragment of the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10. In one embodiment, a trimerization domain comprises the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10.

[0370] In one embodiment, RNA encoding a trimerization domain (i) comprises the nucleotide sequence of nucleotides 7 to 87 of SEQ ID NO: 11, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 7 to 87 of SEQ ID NO: 11, or a fragment of the nucleotide sequence of nucleotides 7 to 87 of SEQ ID NO: 11, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 7 to 87 of SEQ ID NO: 11; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10, or a functional fragment of the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10. In one embodiment, RNA encoding a trimerization domain (i) comprises the nucleotide sequence of nucleotides 7 to 87 of SEQ ID NO: 11; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10.

[0371] In one embodiment, a trimerization domain comprises the amino acid sequence SEQ ID NO: 10, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 10, or a functional fragment of the amino acid sequence of SEQ ID NO: 10, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 10. In one embodiment, a trimerization domain comprises the amino acid sequence of SEQ ID NO: 10. In one embodiment, RNA encoding a trimerization domain (i) comprises the nucleotide sequence of SEQ ID NO: 11, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 11, or a fragment of the nucleotide sequence of SEQ ID NO: 11, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 11; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 10, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 10, or a functional fragment of the amino acid sequence of SEQ ID NO: 10, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 10. In one embodiment, RNA encoding a trimerization domain (i) comprises the nucleotide sequence of SEQ ID NO: 11; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 10.

[0372] Such trimerization domains are preferably used in order to promote trimerization of the encoded antigenic peptide or protein. More preferably, a trimerization domain as defined herein is fused to an antigenic peptide or protein as defined herein.

[0373] Accordingly, in particularly preferred embodiments, the RNA described herein comprises at least one coding region encoding an antigenic peptide or protein and a trimerization domain as defined herein, said trimerization domain preferably being fused to the antigenic peptide or protein, more preferably to the C-terminus of the antigenic peptide or protein.

[0374] In one embodiment, a vaccine antigen comprises the amino acid sequence of SEQ ID NO: 5, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 5, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 5, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 5. In one embodiment, a vaccine antigen comprises the amino acid sequence of SEQ ID NO: 5.

[0375] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 6, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 6, or a fragment of the nucleotide sequence of SEQ ID NO: 6, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 6; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 5, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 5, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 5, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 5. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 6; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 5.

[0376] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 17, 21, or 26, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 17, 21, or 26, or a fragment of the nucleotide sequence of SEQ ID NO: 17, 21, or 26, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 17, 21, or 26; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 5, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 5, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 5, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 5. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 17, 21, or 26; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 5.

[0377] In one embodiment, a vaccine antigen comprises the amino acid sequence of SEQ ID NO: 18, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 18, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 18, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 18. In one embodiment, a vaccine antigen comprises the amino acid sequence of SEQ ID NO: 18.

[0378] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29. In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29.

[0379] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 824 of SEQ ID NO: 30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 824 of SEQ ID NO: 30, or a fragment of the nucleotide sequence of nucleotides 54 to 824 of SEQ ID NO: 30, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 824 of SEQ ID NO: 30; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 824 of SEQ ID NO: 30; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29.

[0380] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31. In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 833 of SEQ ID NO: 32, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 833 of SEQ ID NO: 32, or a fragment of the nucleotide sequence of nucleotides 54 to 833 of SEQ ID NO: 32, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 833 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 833 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31.

[0381] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29. In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29.

[0382] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 111 to 824 of SEQ ID NO: 30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 111 to 824 of SEQ ID NO: 30, or a fragment of the nucleotide sequence of nucleotides 111 to 824 of SEQ ID NO: 30, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 111 to 824 of SEQ ID NO: 30; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 111 to 824 of SEQ ID NO: 30; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29.

[0383] In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31. In one embodiment, a vaccine antigen comprises the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31.

[0384] In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 120 to 833 of SEQ ID NO: 32, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 120 to 833 of SEQ ID NO: 32, or a fragment of the nucleotide sequence of nucleotides 120 to 833 of SEQ ID NO: 32, or the nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 120 to 833 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31, or the amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31. In one embodiment, RNA encoding a vaccine antigen (i) comprises the nucleotide sequence of nucleotides 120 to 833 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31.

[0385] Transmembrane Domain

[0386] In some embodiments, an RNA described herein comprises a sequence that encodes a membrane association element (e.g., a heterologous membrane association element), such as a transmembrane domain. A transmembrane domain can be N-terminal, C-terminal, or internal to an encoded polypeptide. A coding sequence of a transmembrane element is typically placed in frame (i.e., in the same reading frame), 5', 3', or internal to coding sequences of sequences (e.g., sequences encoding polypeptide(s)) with which it is to be linked. In some embodiments, a transmembrane domain comprises or is a transmembrane domain of Hemagglutinin (HA) of Influenza virus, Env of HIV-1, equine infectious anaemia virus (EIAV), murine leukaemia virus (MLV), mouse mammary tumor virus, G protein of vesicular stomatitis virus (VSV), Rabies virus, or a seven transmembrane domain receptor.

[0387] According to certain embodiments, a transmembrane domain is fused, either directly or through a linker, e.g., a glycine / serine linker, to a SARS-CoV-2 S protein, a variant thereof, or a fragment thereof, i.e., the antigenic peptide or protein. Accordingly, in one embodiment, a transmembrane domain is fused to a SARS-CoV-2 S polypeptide or an immunogenic fragment thereof (antigenic peptides or proteins), which may optionally be fused to a signal peptide and / or trimerization domain as described above.

[0388] Secretory Signals

[0389] Such transmembrane domains are preferably located at the C-terminus of the antigenic peptide or protein, without being limited thereto. Preferably, such transmembrane domains are located at the C-terminus of the trimerization domain, if present, without being limited thereto. In one embodiment, a trimerization domain is present between the SARS-CoV-2 S protein, a variant thereof, or a fragment thereof, i.e., the antigenic peptide or protein, and th...

Claims

Claims1. A composition or medical preparation comprising an RNA encoding a SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein the SARS-CoV-2 S polypeptide or fragment comprises:(a) an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:1:(1) D985P, V987P, F817P, A892P, A899P, and A942P;(2) K986P, V987P, F817P, A892P, A899P, and A942P;(3) D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(4) K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(5) D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(6) D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S;(7) K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; or(8) D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S;(b) an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(c) an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(d) an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

2. The composition or medical preparation of claim 1, wherein the RNA comprises a modified nucleoside in place of uridine.

3. The composition or medical preparation of claim 1 or 2, wherein the RNA comprises modified uridines in place of all uridines.

4. The composition or medical preparation of any one of claims 1 to 3, wherein the RNA comprises N1-methyl-pseudouridine (m1ψ) in place of all uridines.

5. The composition or medical preparation of any one of claims 1 to 4, wherein theRNA comprises a 5' cap.

6. The composition or medical preparation of claim 5, wherein the 5' cap is or comprises m27'3'-OGppp(m12'-O)ApG.

7. The composition or medical preparation of any one of claims 1 to 6, wherein the RNA comprises a 5'-UTR that is or comprises a modified human alpha-globin 5'-UTR.

8. The composition or medical preparation of any one of claims 1 to 7, wherein the RNA comprises a 5' UTR comprising the nucleotide sequence of SEQ ID NO: 12, or a nucleotide sequence that is at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO: 12.

9. The composition or medical preparation of any one of claims 1 to 8, wherein the RNA comprises a 3'-UTR that is or comprises a first sequence from the amino terminal enhancer of split (AES) messenger RNA and a second sequence from the mitochondrial encoded 12S ribosomal RNA.

10. The composition or medical preparation of any one of claims 1 to 9, wherein the RNA comprises a 3' UTR comprising the nucleotide sequence of SEQ ID NO: 13, or a nucleotide sequence that is at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO: 13.

11. The composition or medical preparation of any one of claims 1 to 10, wherein the RNA comprises a poly-A sequence.

12. The composition or medical preparation of claim 11, wherein the poly-A sequence comprises at least 100 nucleotides.

13. The composition or medical preparation of claim 11 or 12, wherein the poly-A sequence comprises 30 adenine nucleotides followed by 70 adenine nucleotides, wherein the 30 adenine nucleotides and 70 adenine nucleotides are separated by a linker sequence.

14. The composition or medical preparation of any one of claims 11 to 13, wherein the poly-A sequence comprises or consists of the nucleotide sequence of SEQ ID NO: 14, or a nucleotide sequence that is at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO: 14.

15. The composition or medical preparation of any one of claims 1 to 14, wherein the RNA is formulated or is to be formulated for intramuscular administration.

16. The composition or medical preparation of any one of claims 1 to 15, wherein the RNA is formulated or is to be formulated as particles.

17. The composition or medical preparation of claim 16, wherein the particles are lipid nanoparticles (LNPs) or lipoplex (LPX) particles.

18. The composition or medical preparation of claim 17, wherein the LNPs comprise a cationica I ly ionizable lipid, a neutral lipid, a sterol and a polymer-lipid conjugate.

19. The composition or medical preparation of claim 17, wherein the lipoplex particles are obtainable by mixing the RNA with liposomes.

20. The composition or medical preparation of any one of claims 1 to 19, wherein the RNA is mRNA or saRNA.

21. The composition or medical preparation of any one of claims 1 to 20, which is a pharmaceutical composition.

22. The composition or medical preparation of any one of claims 1 to 21, which is a vaccine.

23. The composition or medical preparation of claim 21 or 22, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers, diluents and / or excipients.

24. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:1:(1) D985P, V987P, F817P, A892P, A899P, and A942P;(2) K986P, V987P, F817P, A892P, A899P, and A942P;(3) D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(4) K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(5) D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(6) D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S;(7) K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; or(8) D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S.

25. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

26. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SE ID NO:1; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, andR682S.

27. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

28. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SE ID NO:69; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%identity to SEQ ID NO:1, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:1:(1) D985P, V987P, F817P, A892P, A899P, and A942P;(2) K986P, V987P, F817P, A892P, A899P, and A942P;(3) D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(4) K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(5) D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(6) D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S;(7) K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; or(8) D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S.

29. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, andR682S.

30. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

31. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

32. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:1:(1) D985P, V987P, F817P, A892P, A899P, and A942P;(2) K986P, V987P, F817P, A892P, A899P, and A942P;(3) D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(4) K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(5) D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(6) D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S;(7) K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; or(8) D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, andR685S.

33. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

34. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, andR682S.

35. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

36. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or SEQ ID NQ:105; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%identity to SEQ ID NO:1, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:1:(1) D985P, V987P, F817P, A892P, A899P, and A942P;(2) K986P, V987P, F817P, A892P, A899P, and A942P;(3) D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(4) K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(5) D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S;(6) D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S;(7) K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; or(8) D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S.

37. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or SEQ ID NQ:105; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, andR682S.

38. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or SEQ ID NO:105; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

39. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or SEQ ID NQ:105; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

40. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, and A942P; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

41. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity toSEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, and A942P; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85% 90% 91% 92% 93% 94% 95% 96% 97% 98% 99% or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

42. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, andR682S.

43. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

44. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

45. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

46. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity toSEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

47. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises one of the following sets of amino substitutions relative to SEQ ID NO:69:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, andR682S.

48. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, and A942P; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

49. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, and A942P; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

50. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

51. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity toSEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

52. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, andR682S.

53. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

54. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

55. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

56. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity toSEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, and A942P; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85% 90% 91% 92% 93% 94% 95% 96% 97% 98% 99% or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

57. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, and A942P; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, andR680S.

58. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

59. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

60. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, K986P, V987P, F817P, A892P, A899P, A942P, D614G, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

61. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity toSEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

62. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, andR680S.

63. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1, and comprises the following substitutions relative to SEQ ID NO:1: D985P, K986P, V987P, F817P, A892P, A899P, A942P, R682G, R683S, and R685S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

64. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: D982P, V984P, F814P, A889P, A896P, and A939P; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

65. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: K983P, V984P, F814P, A889P, A896P, and A939P; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

66. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity toSEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

67. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, andR682S.

68. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:70:(1) D982P, V984P, F814P, A889P, A896P, and A939P;(2) K983P, V984P, F814P, A889P, A896P, and A939P;(3) D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S;(4) K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; or(5) D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S.

69. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: D982P, V984P, F814P, A889P, A896P, and A939P; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

70. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: K983P, V984P, F814P, A889P, A896P, and A939P; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

71. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity toSEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

72. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, andR680S.

73. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:69, and comprises the following substitutions relative to SEQ ID NO:69: D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

74. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises the following substitutions relative to SEQ ID NQ:70: D982P, V984P, F814P, A889P, A896P, and A939P; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

75. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises the following substitutions relative to SEQ ID NO:70: K983P, V984P, F814P, A889P, A896P, and A939P; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

76. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity toSEQ ID NO:70, and comprises the following substitutions relative to SEQ ID NO:70: D982P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

77. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:70, and comprises the following substitutions relative to SEQ ID NQ:70: K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NQ:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NO: 104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, andR680S.

78. A composition or medical preparation comprising a first RNA encoding a first SARS- CoV-2 S polypeptide or an immunogenic fragment thereof, and a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein:(a) the first SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:70, and comprises the following substitutions relative to SEQ ID NO:70: D982P, K983P, V984P, F814P, A889P, A896P, A939P, R679G, R680S, and R682S; and(b) the second SARS-CoV-2 S polypeptide or fragment comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:104 or 105, and comprises one of the following sets of amino substitutions relative to SEQ ID NQ:104 or 105:(1) D980P, V982P, F812P, A887P, A894P, and A937P;(2) K981P, V982P, F812P, A887P, A894P, and A937P;(3) D980P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S;(4) K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S; or(5) D980P, K981P, V982P, F812P, A887P, A894P, A937P, R677G, R678S, and R680S.

79. The composition or medical preparation of any one of claims 24 to 78, wherein the first RNA and the second RNA each comprise a modified nucleoside in place of uridine.

80. The composition or medical preparation of any one of claims 24 to 79, wherein the first RNA and the second RNA each comprise modified uridines in place of all uridines.

81. The composition or medical preparation of any one of claims 24 to 80, wherein the first RNA and the second RNA each comprise N1-methyl-pseudouridine (m1ψ) in place of all uridines.

82. The composition or medical preparation of any one of claims 24 to 81, wherein the first RNA and the second RNA each comprise a 5' cap.

83. The composition or medical preparation of claim 82, wherein the 5' cap comprises m27'3'-OGppp(m12'-O)ApG.

84. The composition or medical preparation of any one of claims 24 to 83, wherein the first RNA and the second RNA each comprise a 5'-UTR that is or comprises a modified human alpha-globin 5'-UTR.

85. The composition or medical preparation of any one of claims 24 to 84, wherein the first RNA and the second RNA each comprise a 5' UTR comprising the nucleotide sequence of SEQ ID NO: 12, or a nucleotide sequence that is at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO: 12.

86. The composition or medical preparation of any one of claims 24 to 85, wherein the first RNA and the second RNA each comprise a 3'-UTR that is or comprises a first sequence from the amino terminal enhancer of split (AES) messenger RNA and a second sequence from the mitochondrial encoded 12S ribosomal RNA.

87. The composition or medical preparation of any one of claims 24 to 86, wherein the first RNA and the second RNA each comprise a 3' UTR comprising the nucleotide sequence of SEQ ID NO: 13, or a nucleotide sequence that is at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO: 13.

88. The composition or medical preparation of any one of claims 24 to 87, wherein the first RNA and the second RNA each comprise a poly-A sequence.

89. The composition or medical preparation of claim 88, wherein the first RNA and the second RNA each comprise a poly-A sequence that comprises at least 100 nucleotides.

90. The composition or medical preparation of claim 88 or 89, wherein the first RNA and the second RNA each comprise a poly-A sequence that comprises 30 adenine nucleotides followed by 70 adenine nucleotides, wherein the 30 adenine nucleotides and 70 adenine nucleotides are separated by a linker sequence.

91. The composition or medical preparation of any one of claims 88 to 90, wherein the first RNA and the second RNA each comprise a poly-A sequence that comprises or consists of the nucleotide sequence of SEQ ID NO: 14, or a nucleotide sequence that is at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO: 14.

92. The composition or medical preparation of any one of claims 24 to 91, wherein the first RNA and the second RNA are each formulated or to be formulated for intramuscular administration.

93. The composition or medical preparation of any one of claims 24 to 92, wherein the first RNA and the second RNA are each formulated or to be formulated as particles.

94. The composition or medical preparation of claim 93, wherein the first RNA and the second RNA are each to be formulated as lipid nanoparticles (LNPs) or lipoplex (LPX) particles.

95. The composition or medical preparation of claim 94, wherein the LNPs comprise a cationica I ly ionizable lipid, a neutral lipid, a sterol and a polymer-lipid conjugate.

96. The immunogenic composition of claim 94 or 95, wherein the first RNA and the second RNA are formulated in separate LNPs.

97. The immunogenic composition of claim 94 or 95, wherein the first RNA and the second RNA are formulated in the same LNP.

98. The composition or medical preparation of claim 94, wherein the lipoplex particles are obtainable by mixing the RNA with liposomes.

99. The composition or medical preparation of any one of claims 24 to 98, wherein the first RNA and the second RNA are each mRNA, or wherein the first RNA and the second RNA are each saRNA.

100. The composition or medical preparation of any one of claims 24 to 99, which is a pharmaceutical composition.

101. The composition or medical preparation of any one of claims 24 to 100, which is a vaccine.

102. The composition or medical preparation of claim 100 or 101, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers, diluents and / or excipients.

103. A method of inducing an immune response in a subject, the method comprising administering to the subject the composition or medical preparation of any one of claims 1- 23 thereby inducing an immune response in the subject.

104. The method of claim 103, wherein the SARS-CoV-2 S polypeptide comprises an amino acid sequence that does not comprise a D985P substitution relative to SEQ ID NO:1; does not comprise a D982P substitution relative to SEQ ID NO:69 or SEQ ID NQ:70, or does not comprise a D980P substitution relative to SEQ ID NQ:104 or SEQ ID NQ:105.

105. The method of claim 103 or 104, further comprising administering a second RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein the second SARS-CoV-2 S polypeptide or immunogenic fragment is a SARS-CoV-2 S polypeptide of an Omicron variant that is not a BA.1 Omicron variant.

106. The method of claim 103 or 104, further comprising administering a second, different RNA encoding a second SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, wherein the second SARC-CoV-2 S polypeptide or fragment is selected from an SARS- CoV-2 S polypeptide or fragment recited in claim 1.

107. A method of inducing an immune response in a subject, the method comprising administering to the subject the composition or medical preparation of any one of claims 24- 102, thereby inducing an immune response in the subject.

108. The method of claim 107, wherein the SARS-CoV-2 S polypeptide comprises an amino acid sequence that does not comprise a D985P substitution relative to SEQ ID NO:1; does not comprise a D982P substitution relative to SEQ ID NO:69 or SEQ ID NQ:70, or does not comprise a D980P substitution relative to SEQ ID NQ:104 or SEQ ID NQ:105.

109. The method of claim 107 or 108, further comprising administering a second composition or medical preparation, wherein the second composition or medical preparation comprises an RNA encoding an SARS-CoV-2 S polypeptide or an immunogenic fragment of an Omicron variant that is not a BA.1 Omicron variant.

110. The method of claim 107 or 108, further comprising administering a second composition or medical preparation, wherein the second composition or medical preparation comprises a third RNA encoding a third SARS-CoV-2 S polypeptide or an immunogenic fragment thereof, and a fourth RNA encoding a fourth SARS-CoV-2 S polypeptide or an immunogenic fragment thereof.

111. The method of claim 110, wherein the third RNA encodes an SARS-CoV-2 S polypeptide or an immunogenic fragment thereof that is a first or a second SARS-CoV-2 S polypeptide or immunogenic fragment thereof recited in any one of claims 24-102, and wherein the third RNA encodes a SARS-CoV-2 S polypeptide or fragment that is different fromthe first SARS-CoV-2 S polypeptide or fragment encoded by the first RNA and / or that is different from the second SARS-CoV-2 S polypeptide or fragment encoded by the second RNA.

112. The method of claim 110, wherein the fourth RNA encodes an SARS-CoV-2 S polypeptide or an immunogenic fragment thereof that is a first or a second SARS-CoV-2 S polypeptide or immunogenic fragment thereof recited in any one of claims 24-102, and wherein the fourth RNA encodes a SARS-CoV-2 S polypeptide or fragment that is different from the first SARS-CoV-2 S polypeptide or fragment encoded by the first RNA and / or that is different from the second SARS-CoV-2 S polypeptide or fragment encoded by the second RNA.

113. The method of claim 110, wherein the third RNA encodes an SARS-CoV-2 S polypeptide or an immunogenic fragment thereof that is a first or a second SARS-CoV-2 S polypeptide or immunogenic fragment thereof recited in any one of claims 24-102, and wherein the third RNA encodes a SARS-CoV-2 S polypeptide or fragment that is different from the first SARS-CoV-2 S polypeptide or fragment encoded by the first RNA and that is different from the second SARS-CoV-2 S polypeptide or fragment encoded by the second RNA.

114. The method of claim 110, wherein the fourth RNA encodes an SARS-CoV-2 S polypeptide or an immunogenic fragment thereof that is a first or a second SARS-CoV-2 S polypeptide or immunogenic fragment thereof recited in any one of claims 24-102, and wherein the fourth RNA encodes a SARS-CoV-2 S polypeptide or fragment that is different from the first SARS-CoV-2 S polypeptide or fragment encoded by the first RNA and that is different from the second SARS-CoV-2 S polypeptide or fragment encoded by the second RNA.

115. The method of claim 110, wherein the third RNA encodes an SARS-CoV-2 S polypeptide or an immunogenic fragment thereof that is a first or a second SARS-CoV-2 S polypeptide or immunogenic fragment thereof recited in any one of claims 24-102, wherein the third RNA encodes a SARS-CoV-2 S polypeptide or fragment that is different from the first SARS-CoV-2 S polypeptide or fragment encoded by the first RNA and that is different from the second SARS-CoV-2 S polypeptide or fragment encoded by the second RNA, wherein thefourth RNA encodes an SARS-CoV-2 S polypeptide or an immunogenic fragment thereof that is a first or a second SARS-CoV-2 S polypeptide or immunogenic fragment thereof recited in any one of claims 24-102, wherein the fourth RNA encodes a SARS-CoV-2 S polypeptide or fragment that is different from the first SARS-CoV-2 S polypeptide or fragment encoded by the first RNA and that is different from the second SARS-CoV-2 S polypeptide or fragment encoded by the second RNA.

116. The method of claim 115, wherein each of the first, second, third, and fourth RNAs encodes a different SARS-CoV-2 S polypeptide or immunogenic fragment thereof.

117. A method of inducing an immune response in a subject, the method comprising administering to the subject (i) the composition or medical preparation of any one of claims 1-23 and (ii) the composition or medical preparation of any one of claims 24-102, thereby inducing an immune response in the subject.

118. The method of claim 117, wherein the subject receiving the composition or medical preparation of (ii) was previously administered with the composition or medical preparation of (i).

119. The method of claim 117, wherein the subject receiving the composition or medical preparation of (i) was previously administered with the composition or medical preparation of (ii).

120. The method of claim 117, wherein the composition or medical preparation of (i) and the composition or medical preparation of (ii) are administered together as a multivalent vaccine.